BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350-391. [PMID: 19406039 DOI: 10.6004/jnccn.2009.0027] [Cited by in Crossref: 299] [Cited by in F6Publishing: 324] [Article Influence: 23.0] [Reference Citation Analysis]
Number Citing Articles
1 Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Croisé-Laurent V, Barraud H, Ayav A, Bronowicki JP, Peiffert D. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol. 2015;115:211-216. [PMID: 26028227 DOI: 10.1016/j.radonc.2015.04.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 11.7] [Reference Citation Analysis]
2 Matsuyama R, Yabusita Y, Homma Y, Kumamoto T, Endo I. Essential updates 2019/2020: Surgical treatment of gallbladder cancer. Ann Gastroenterol Surg 2021;5:152-61. [PMID: 33860135 DOI: 10.1002/ags3.12434] [Reference Citation Analysis]
3 Cheng H, Xue J, Yang S, Chen Y, Wang Y, Zhu Y, Wang X, Kuang D, Ruan Q, Duan Y. Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development. Oncotarget. 2017;8:47984-47997. [PMID: 28624790 DOI: 10.18632/oncotarget.18207] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
4 Chellappan DK, Leng KH, Jia LJ, Aziz NABA, Hoong WC, Qian YC, Ling FY, Wei GS, Ying T, Chellian J, Gupta G, Dua K. The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review. Biomedicine & Pharmacotherapy 2018;102:1127-44. [DOI: 10.1016/j.biopha.2018.03.061] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
5 Liu Z, Lin Y, Zhang J, Zhang Y, Li Y, Liu Z, Li Q, Luo M, Liang R, Ye J. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38:447. [PMID: 31684985 DOI: 10.1186/s13046-019-1412-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 15.7] [Reference Citation Analysis]
6 Nacif LS, Hessheimer AJ, Rodríguez Gómez S, Montironi C, Fondevila C. Infiltrative xanthogranulomatous cholecystitis mimicking aggressive gallbladder carcinoma: A diagnostic and therapeutic dilemma. World J Gastroenterol 2017; 23(48): 8671-8678 [PMID: 29358875 DOI: 10.3748/wjg.v23.i48.8671] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Nishino H, Hollandsworth HM, Tashiro Y, Yamamoto J, Amirfakhri S, Filemoni F, Sugisawa N, Hoffman RM, Bouvet M. Ligation Method to Specifically Label a Liver Segment With Indocyanine Green in an Orthotopic Nude-Mouse Liver-Metastasis Model. In Vivo 2020;34:3159-62. [PMID: 33144419 DOI: 10.21873/invivo.12150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ren B, Guo Q, Yang Y, Liu L, Wei S, Chen W, Tian Y. A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma. Radiat Oncol 2020;15:15. [PMID: 31941520 DOI: 10.1186/s13014-020-1459-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
9 Rho YS, Pagano I, Wong LL, Kwee SA, Acoba JD. Factors and Survival Implications associated with biopsy of hepatocellular carcinoma. HPB (Oxford) 2021;23:1054-60. [PMID: 33229278 DOI: 10.1016/j.hpb.2020.11.001] [Reference Citation Analysis]
10 Jiang W, Zeng ZC. Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma? Oncology. 2013;84 Suppl 1:69-74. [PMID: 23428862 DOI: 10.1159/000345893] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
11 Yin H, Peng X, Ren P, Cheng B, Li S, Qin C. MicroRNAs as a novel class of diagnostic biomarkers in detection of hepatocellular carcinoma: a meta-analysis. Tumour Biol 2014;35:12317-26. [PMID: 25204672 DOI: 10.1007/s13277-014-2544-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
12 Yang HJ, Lee JH, Lee DH, Yu SJ, Kim YJ, Yoon JH, Kim HC, Lee JM, Chung JW, Yi NJ, Lee KW, Suh KS, Lee HS. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. Radiology 2014;271:909-18. [PMID: 24520944 DOI: 10.1148/radiol.13131760] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
13 Cai X, Chen Z, Chen J, Ma X, Bai M, Wang T, Chen X, Wu D, Wei L, Li X, Lin Q, Wen J, Ruan D, Lin Z, Dong M, Wu X. Albumin-to-Alkaline Phosphatase Ratio as an Independent Prognostic Factor for Overall Survival of Advanced Hepatocellular Carcinoma Patients without Receiving Standard Anti-Cancer Therapies. J Cancer 2018;9:189-97. [PMID: 29290785 DOI: 10.7150/jca.21799] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
14 Zuo TY, Liu FY, Wang MQ, Chen XX. Transcatheter Arterial Chemoembolization Combined with Simultaneous Computed Tomography-guided Radiofrequency Ablation for Large Hepatocellular Carcinomas. Chin Med J (Engl) 2017;130:2666-73. [PMID: 29133753 DOI: 10.4103/0366-6999.218002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
15 Chao Y, Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer. 2015;136:1458-1467. [PMID: 25099027 DOI: 10.1002/ijc.29126] [Cited by in Crossref: 69] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
16 Voiosu T, Voiosu A, Danielescu C, Popescu D, Puscasu C, State M, Chiricuţă A, Mardare M, Spanu A, Bengus A, Busuioc B, Zamfir M, Ginghina O, Barbu M, Nitipir C, Mateescu B. Unmet needs in the diagnosis and treatment of Romanian patients with bilio-pancreatic tumors: results of a prospective observational multicentric study. Rom J Intern Med 2021;59:286-95. [PMID: 33657285 DOI: 10.2478/rjim-2021-0009] [Reference Citation Analysis]
17 Miyahara K, Nouso K, Yamamoto K. Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World J Gastroenterol 2014; 20(15): 4151-4159 [PMID: 24764653 DOI: 10.3748/wjg.v20.i15.4151] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
18 Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, Morosi C, Lanocita R, Romito R, Chiesa C, Maccauro M, Marchianò A, Mazzaferro V. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol 2018;68:724-32. [PMID: 29331342 DOI: 10.1016/j.jhep.2017.12.026] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 13.3] [Reference Citation Analysis]
19 Lipnik AJ, Brown DB. Image-Guided Percutaneous Abdominal Mass Biopsy. Radiologic Clinics of North America 2015;53:1049-59. [DOI: 10.1016/j.rcl.2015.05.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
20 Vega EA, Vinuela E, Sanhueza M, Mege R, Caracci M, Diaz C, Diaz A, Okuno M, Joechle K, Goumard C, Chun YS, Tzeng CD, Lee JE, Vauthey JN, Conrad C. Positive cystic duct margin at index cholecystectomy in incidental gallbladder cancer is an important negative prognosticator. Eur J Surg Oncol 2019;45:1061-8. [PMID: 30704808 DOI: 10.1016/j.ejso.2019.01.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Pan JJ, Javle M, Thinn MM, Hsueh CT, Hsueh CT. Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. Hepat Med 2010;2:147-55. [PMID: 24367212 DOI: 10.2147/HMER.S7123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
22 Chang Y, Li Q, Wu Q, Chi L, Bi X, Zeng Q, Huo H. Impact of surgical strategies on the survival of gallbladder cancer patients: analysis of 715 cases. World J Surg Oncol 2020;18:142. [PMID: 32590998 DOI: 10.1186/s12957-020-01915-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Malek NP, Schmidt S, Huber P, Manns MP, Greten TF. The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int 2014;111:101-6. [PMID: 24622679 DOI: 10.3238/arztebl.2014.0101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 32] [Article Influence: 0.7] [Reference Citation Analysis]
24 Schmidt S, Follmann M, Malek N, Manns MP, Greten TF. Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:1779-1786. [PMID: 21875430 DOI: 10.1111/j.1440-1746.2011.06891.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
25 Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist. 2010;15:168-181. [PMID: 20147507 DOI: 10.1634/theoncologist.2009-0302] [Cited by in Crossref: 184] [Cited by in F6Publishing: 164] [Article Influence: 15.3] [Reference Citation Analysis]
26 Chang SC, Choo WQ, Toh HC, Ding JL. SAG-UPS attenuates proapoptotic SARM and Noxa to confer survival advantage to early hepatocellular carcinoma. Cell Death Discov 2015;1:15032. [PMID: 27551463 DOI: 10.1038/cddiscovery.2015.32] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
27 Kulik L. Is radioembolization ready for the barcelona clinic liver cancer staging system? Hepatology 2010;52:1528-30. [DOI: 10.1002/hep.24030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 He C, Peng W, Liu X, Li C, Li X, Wen TF. Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 2019;98:e16557. [PMID: 31374020 DOI: 10.1097/md.0000000000016557] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
29 Cheng AL, Amarapurkar D, Chao Y, Chen P, Geschwind J, Goh KL, Han K, Kudo M, Lee HC, Lee R, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan C, Tanwandee T, Teng G, Park J. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int 2014;34:174-83. [DOI: 10.1111/liv.12314] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
30 Yoon HI, Seong J. Optimal Selection of Radiotherapy as Part of a Multimodal Approach for Hepatocellular Carcinoma. Liver Cancer 2016;5:139-51. [PMID: 27386432 DOI: 10.1159/000367762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
31 Bender Ignacio R, Ghadrshenas M, Low D, Orem J, Casper C, Phipps W. HIV Status and Associated Clinical Characteristics Among Adult Patients With Cancer at the Uganda Cancer Institute. J Glob Oncol 2018;4:1-10. [PMID: 30241139 DOI: 10.1200/JGO.17.00112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
32 Cho Y, Lee JH, Lee DH, Cho EJ, Yu SJ, Yi NJ, Lee KW, Kim YJ, Yoon JH, Suh KS. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. Oncotarget 2017;8:47555-64. [PMID: 28548930 DOI: 10.18632/oncotarget.17733] [Reference Citation Analysis]
33 Sandrasegaran K, Menias CO. Imaging and Screening of Cancer of the Gallbladder and Bile Ducts. Radiologic Clinics of North America 2017;55:1211-22. [DOI: 10.1016/j.rcl.2017.06.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
34 Padia SA, Shivaram G, Bastawrous S, Bhargava P, Vo NJ, Vaidya S, Valji K, Harris WP, Hippe DS, Kogut MJ. Safety and Efficacy of Drug-eluting Bead Chemoembolization for Hepatocellular Carcinoma: Comparison of Small-versus Medium-size Particles. Journal of Vascular and Interventional Radiology 2013;24:301-6. [DOI: 10.1016/j.jvir.2012.11.023] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 6.2] [Reference Citation Analysis]
35 Xu M, Hu J, Zhou B, Zhong Y, Lin N, Xu R. TRIM29 prevents hepatocellular carcinoma progression by inhibiting Wnt/β-catenin signaling pathway. Acta Biochimica et Biophysica Sinica 2019;51:68-77. [DOI: 10.1093/abbs/gmy151] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
36 Li D, Madoff DC. Portal vein embolization for induction of selective hepatic hypertrophy prior to major hepatectomy: rationale, techniques, outcomes and future directions. Cancer Biol Med. 2016;13:426-442. [PMID: 28154774 DOI: 10.20892/j.issn.2095-3941.2016.0083] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
37 Wang F, Xu C, Li G, Lv P, Gu J. Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma. Exp Cell Res 2021;409:112910. [PMID: 34801560 DOI: 10.1016/j.yexcr.2021.112910] [Reference Citation Analysis]
38 Yan L, Chen Y, Zhou J, Zhao H, Zhang H, Wang G. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma. Int J Infect Dis 2018;67:92-7. [PMID: 29229500 DOI: 10.1016/j.ijid.2017.12.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
39 Kim SH, Won KS, Choi BW, Jo I, Zeon SK, Chung WJ, Kwon JH. Usefulness of F-18 FDG PET/CT in the Evaluation of Early Treatment Response After Interventional Therapy for Hepatocellular Carcinoma. Nucl Med Mol Imaging. 2012;46:102-110. [PMID: 24900042 DOI: 10.1007/s13139-012-0138-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
40 Goetze TO, Paolucci V. [Incidental T1b-T3 gallbladder carcinoma. Extended cholecystectomy as an underestimated prognostic factor-results of the German registry]. Chirurg. 2014;85:131-138. [PMID: 24005717 DOI: 10.1007/s00104-013-2587-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
41 Yu Z, Xu J, Wang J. Isolated brain metastases prior to locoregional recurrence in hilar cholangiocarcinoma. Mol Clin Oncol 2017;6:899-902. [PMID: 28588786 DOI: 10.3892/mco.2017.1253] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
42 Wang CY, Xia JG, Yang ZQ, Zhou WZ, Chen WH, Qi CJ, Gu JP, Wang Q. Transarterial chemoembolization with medium-sized doxorubicin-eluting Callisphere is safe and effective for patients with hepatocellular carcinoma. Sci Rep 2020;10:4434. [PMID: 32157110 DOI: 10.1038/s41598-020-61209-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
43 Zhang P, Yang Y, Wen F, He X, Tang R, Du Z, Zhou J, Zhang J, Li Q. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2015;27:853-859. [PMID: 25919775 DOI: 10.1097/meg.0000000000000373] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
44 Kobayashi S, Nagano H, Tomokuni A, Gotoh K, Sakai D, Hatano E, Seo S, Terajima H, Uchida Y, Ajiki T, Satake H, Kamei K, Tohyama T, Hirose T, Ikai I, Morita S, Ioka T. A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery 2019;270:230-7. [DOI: 10.1097/sla.0000000000002865] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 6.3] [Reference Citation Analysis]
45 Panayotova GG, Paterno F, Guarrera JV, Lunsford KE. Liver Transplantation for Cholangiocarcinoma: Insights into the Prognosis and the Evolving Indications. Curr Oncol Rep. 2020;22:49. [PMID: 32297105 DOI: 10.1007/s11912-020-00910-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
46 Gavriilidis P, Roberts KJ, Askari A, Sutcliffe RP, Huo TL, Liu PH, Hidalgo E, Compagnon P, Lim C, Azoulay D. Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument. J Hepatol. 2017;67:991-998. [PMID: 28690176 DOI: 10.1016/j.jhep.2017.06.028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
47 Nomura R, Tokumura H, Furihata M. Laparoscopic repair of a diaphragmatic hernia associated with radiofrequency ablation for hepatocellular carcinoma: lessons from a case and the review of the literature. Int Surg. 2014;99:384-390. [PMID: 25058770 DOI: 10.9738/intsurg-d-14-00025.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
48 Fetzer DT, Rodgers SK, Harris AC, Kono Y, Wasnik AP, Kamaya A, Sirlin C. Screening and Surveillance of Hepatocellular Carcinoma: An Introduction to Ultrasound Liver Imaging Reporting and Data System. Radiol Clin North Am 2017;55:1197-209. [PMID: 28991560 DOI: 10.1016/j.rcl.2017.06.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
49 Wiesweg M, Aydin S, Koeninger A, Stein A, Schara U, van Roye C, Hense J, Welt A, Schuler M. Administration of Gemcitabine for Metastatic Adenocarcinoma during Pregnancy: A Case Report and Review of the Literature. AJP Rep 2014;4:17-22. [PMID: 25032054 DOI: 10.1055/s-0034-1368091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
50 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol 2017;67:173-83. [PMID: 28323121 DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 90] [Cited by in F6Publishing: 100] [Article Influence: 18.0] [Reference Citation Analysis]
51 Santambrogio R, Opocher E, Costa M, Barabino M, Zuin M, Bertolini E, De Filippi F, Bruno S. Hepatic resection for “BCLC stage A” hepatocellular carcinoma. The prognostic role of alpha-fetoprotein. Ann Surg Oncol. 2012;19:426-434. [PMID: 21732145 DOI: 10.1245/s10434-011-1845-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
52 Scher N, Janoray G, Riet FG, Le Bayon AG, Debbi K, Lévy S, Louisot P, Garaud P, Chajon E, Barillot I, Salamé É, de Crevoisier R, Chapet S, Calais G. [Stereotactic body radiation therapy for hepatocellular carcinoma: Results from a retrospective multicentre study]. Cancer Radiother 2019;23:104-15. [PMID: 30952560 DOI: 10.1016/j.canrad.2018.07.138] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Li D, Kang J, Golas BJ, Yeung VW, Madoff DC. Minimally invasive local therapies for liver cancer. Cancer Biol Med. 2014;11:217-236. [PMID: 25610708 DOI: 10.7497/j.issn.2095-3941.2014.04.001] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
54 Huang H, Liang P, Yu XL, Cheng ZG, Han ZY, Yu J, Liu FY. Safety assessment and therapeutic efficacy of percutaneous microwave ablation therapy combined with percutaneous ethanol injection for hepatocellular carcinoma adjacent to the gallbladder. Int J Hyperthermia 2015;31:40-7. [PMID: 25766386 DOI: 10.3109/02656736.2014.999017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
55 Doussot A, Gonen M, Wiggers JK, Groot-Koerkamp B, DeMatteo RP, Fuks D, Allen PJ, Farges O, Kingham TP, Regimbeau JM, D'Angelica MI, Azoulay D, Jarnagin WR. Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. J Am Coll Surg 2016;223:493-505.e2. [PMID: 27296525 DOI: 10.1016/j.jamcollsurg.2016.05.019] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
56 Park HS, Gross CP, Makarov DV, Yu JB. Immortal Time Bias: A Frequently Unrecognized Threat to Validity in the Evaluation of Postoperative Radiotherapy. International Journal of Radiation Oncology*Biology*Physics 2012;83:1365-73. [DOI: 10.1016/j.ijrobp.2011.10.025] [Cited by in Crossref: 127] [Cited by in F6Publishing: 121] [Article Influence: 12.7] [Reference Citation Analysis]
57 Covey AM, Hussain SM. Liver-Directed Therapy for Hepatocellular Carcinoma: An Overview of Techniques, Outcomes, and Posttreatment Imaging Findings. American Journal of Roentgenology 2017;209:67-76. [DOI: 10.2214/ajr.17.17799] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
58 Qi C, Zhang H, Chen Y, Su S, Wang X, Huang X, Fang C, Li B, Xia X, He P. Effectiveness and safety of indocyanine green fluorescence imaging-guided hepatectomy for liver tumors: A systematic review and first meta-analysis. Photodiagnosis Photodyn Ther 2019;28:346-53. [PMID: 31600578 DOI: 10.1016/j.pdpdt.2019.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
59 Salman A, Simoneau E, Hassanain M, Chaudhury P, Boucher LM, Valenti D, Cabrera T, Nudo C, Metrakos P. Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma. Curr Oncol 2016;23:e472-80. [PMID: 27803608 DOI: 10.3747/co.23.2827] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
60 Wang Z, Li Y, Jiang W, Yan J, Dai J, Jiao B, Yin Z, Zhang Y. Simple Cholecystectomy Is Adequate for Patients With T1b Gallbladder Adenocarcinoma < 1 cm in Diameter. Front Oncol 2019;9:409. [PMID: 31192121 DOI: 10.3389/fonc.2019.00409] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
61 Khan I, Iqbal Z, Khan A, Hassan M, Nasir F, Raza A, Ahmad L, Khan A, Akhlaq Mughal M. A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. Journal of Chromatography B 2016;1033-1034:261-70. [DOI: 10.1016/j.jchromb.2016.08.029] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
62 Gavriilidis P, Askari A, Azoulay D. To Resect or Not to Resect Extrahepatic Bile Duct in Gallbladder Cancer? J Clin Med Res 2017;9:81-91. [PMID: 28090223 DOI: 10.14740/jocmr2804w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
63 Meriggi F, Graffeo M. Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. Cancers (Basel) 2021;13:584. [PMID: 33540870 DOI: 10.3390/cancers13030584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Witjes CD, Verhoef C, Kwekkeboom DJ, Dwarkasing RS, de Man RA, Ijzermans JN. Is bone scintigraphy indicated in surgical work-up for hepatocellular carcinoma patients? Journal of Surgical Research 2013;181:256-61. [DOI: 10.1016/j.jss.2012.07.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
65 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 27] [Article Influence: 0.5] [Reference Citation Analysis]
66 Nishino H, Hatano E, Seo S, Nitta T, Saito T, Nakamura M, Hattori K, Takatani M, Fuji H, Taura K, Uemoto S. Real-time Navigation for Liver Surgery Using Projection Mapping With Indocyanine Green Fluorescence: Development of the Novel Medical Imaging Projection System. Ann Surg 2018;267:1134-40. [PMID: 28181939 DOI: 10.1097/SLA.0000000000002172] [Cited by in Crossref: 41] [Cited by in F6Publishing: 18] [Article Influence: 13.7] [Reference Citation Analysis]
67 Takahashi H, Mori K, Sekino Y, Okumura T, Hiyama T, Fukuda K, Hasegawa N, Sakai M, Kikuchi S, Takei Y, Iizumi T, Sakurai H, Minami M. Angiographic Findings in Patients with Hepatocellular Carcinoma Previously Treated Using Proton Beam Therapy. J Oncol 2019;2019:3580379. [PMID: 31354819 DOI: 10.1155/2019/3580379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Chen Q, Shu C, Laurence AD, Chen Y, Peng BG, Zhen ZJ, Cai JQ, Ding YT, Li LQ, Zhang YB, Zheng QC, Xu GL, Li B, Zhou WP, Cai SW, Wang XY, Wen H, Peng XY, Zhang XW, Dai CL, Bie P, Xing BC, Fu ZR, Liu LX, Mu Y, Zhang L, Zhang QS, Jiang B, Qian HX, Wang YJ, Liu JF, Qin XH, Li Q, Yin P, Zhang ZW, Chen XP. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut 2018;67:2006-16. [PMID: 29802174 DOI: 10.1136/gutjnl-2018-315983] [Cited by in Crossref: 45] [Cited by in F6Publishing: 57] [Article Influence: 11.3] [Reference Citation Analysis]
69 Stacy S, Hyder O, Cosgrove D, Herman JM, Kamel I, Geschwind JF, Gurakar A, Anders R, Cameron A, Pawlik TM. Patterns of consultation and treatment of patients with hepatocellular carcinoma presenting to a large academic medical center in the US. J Gastrointest Surg 2013;17:1600-8. [PMID: 23780638 DOI: 10.1007/s11605-013-2253-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
70 Chok KS. Management of recurrent hepatocellular carcinoma after liver transplant. World J Hepatol 2015; 7(8): 1142-1148 [PMID: 26052403 DOI: 10.4254/wjh.v7.i8.1142] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
71 Schellhaas B, Strobel D, Stumpf M, Ganslmayer M, Pfeifer L, Goertz RS, Neurath MF, Zopf S. Improvement of clinical management and outcome in hepatocellular carcinoma nowadays compared with historical cohorts. European Journal of Gastroenterology & Hepatology 2018;30:1422-7. [DOI: 10.1097/meg.0000000000001221] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Guan PS, Yuan HX, Wang WP. Characteristics of contrast-enhanced ultrasound in carcinogenesis of gallbladder papillary adenoma: A case report. Clin Hemorheol Microcirc 2021;78:209-14. [PMID: 33579828 DOI: 10.3233/CH-200940] [Reference Citation Analysis]
73 Klein J, Dawson LA, Jiang H, Kim J, Dinniwell R, Brierley J, Wong R, Lockwood G, Ringash J. Prospective Longitudinal Assessment of Quality of Life for Liver Cancer Patients Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015;93:16-25. [PMID: 26279020 DOI: 10.1016/j.ijrobp.2015.04.016] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
74 So H, Oh CH, Song TJ, Ko SW, Hwang JS, Oh D, Park DH, Lee SS, Seo DW, Dong SH, Lee SK, Kim MH. Predictors of stent dysfunction in patients with bilateral metal stents for malignant hilar obstruction. PLoS One 2021;16:e0249096. [PMID: 33780489 DOI: 10.1371/journal.pone.0249096] [Reference Citation Analysis]
75 Lim JH, Chong JU, Kim SH, Park SW, Choi JS, Lee WJ, Kim KS. Role of common bile duct resection in T2 and T3 gallbladder cancer patients. Ann Hepatobiliary Pancreat Surg. 2018;22:42-51. [PMID: 29536055 DOI: 10.14701/ahbps.2018.22.1.42] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
76 Matsushima H, Takami Y, Ryu T, Yoshitomi M, Tateishi M, Wada Y, Saitsu H. Prognosis of Hepatocellular Carcinoma Patients Who Achieved Long-Term Recurrence-Free Survival After Curative Therapy: Impact of the ALBI Grade. J Gastrointest Surg 2018;22:1230-8. [DOI: 10.1007/s11605-018-3745-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
77 Chen Q, Ayer T, Chhatwal J. Optimal M -Switch Surveillance Policies for Liver Cancer in a Hepatitis C–Infected Population. Operations Research 2018;66:673-96. [DOI: 10.1287/opre.2017.1706] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
78 Ren T, Li Y, Zhang X, Geng Y, Shao Z, Li M, Wu X, Wang XA, Liu F, Wu W, Shu Y, Bao R, Gong W, Dong P, Dang X, Liu C, Liu C, Sun B, Liu J, Wang L, Hong D, Qin R, Jiang X, Zhang X, Xu J, Jia J, Yang B, Li B, Dai C, Cao J, Cao H, Tao F, Zhang Z, Wang Y, Jin H, Cai H, Fei Z, Gu J, Han W, Feng X, Fang L, Zheng L, Zhu C, Wang K, Zhang X, Li X, Jin C, Qian Y, Cui Y, Xu Y, Wang X, Liu H, Hua Y, Liu C, Hao J, Wang C, Li Q, Li X, Liu J, Li M, Qiu Y, Wu B, Zheng J, Chen X, Zhu H, Hua K, Yan M, Wang P, Zang H, Ma X, Hong J, Liu Y. Protocol for a gallbladder cancer registry study in China: the Chinese Research Group of Gallbladder Cancer (CRGGC) study. BMJ Open 2021;11:e038634. [PMID: 33593763 DOI: 10.1136/bmjopen-2020-038634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Joshi K, Mendler M, Gish R, Loomba R, Kuo A, Patton H, Kono Y. Hepatocellular carcinoma surveillance: a national survey of current practices in the USA. Dig Dis Sci 2014;59:3073-7. [PMID: 25027206 DOI: 10.1007/s10620-014-3256-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
80 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1689] [Article Influence: 289.2] [Reference Citation Analysis]
81 Kis B, El-Haddad G, Sheth RA, Parikh NS, Ganguli S, Shyn PB, Choi J, Brown KT. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control 2017;24:1073274817729244. [PMID: 28975829 DOI: 10.1177/1073274817729244] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
82 Nomura A, Ishigami M, Honda T, Kuzuya T, Ishizu Y, Ito T, Kamei H, Onishi Y, Ogura Y, Fujishiro M. Limitation of non-transplant treatment and proper timing for liver transplantation in patients with hepatocellular carcinoma considering long-term survival. Medicine (Baltimore) 2020;99:e21161. [PMID: 32664152 DOI: 10.1097/MD.0000000000021161] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Yang Y, Zhu R. Diagnostic value of circulating microRNAs for hepatocellular carcinoma. Mol Biol Rep 2014;41:6919-29. [PMID: 25030834 DOI: 10.1007/s11033-014-3578-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
84 Holvoet T, Raevens S, Vandewynckel YP, Van Biesen W, Geboes K, Van Vlierberghe H. Systematic review of guidelines for management of intermediate hepatocellular carcinoma using the Appraisal of Guidelines Research and Evaluation II instrument. Dig Liver Dis. 2015;47:877-883. [PMID: 26250948 DOI: 10.1016/j.dld.2015.07.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
85 Spaulding TP, Martin RCG 2nd. Predicting adverse events in patients undergoing hepatectomy-validation of preoperative nomogram and risk score. HPB (Oxford) 2017;19:1112-8. [PMID: 28882456 DOI: 10.1016/j.hpb.2017.08.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
86 Zaydfudim V, Smoot RL, Clark CJ, Kendrick ML, Que FG, Farnell MB, Nagorney DM. Role of operative therapy in non-cirrhotic patients with metastatic hepatocellular carcinoma. J Gastrointest Surg 2012;16:1516-23. [PMID: 22644447 DOI: 10.1007/s11605-012-1918-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
87 Wang K, Kievit FM, Sham JG, Jeon M, Stephen ZR, Bakthavatsalam A, Park JO, Zhang M. Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model. Small 2016;12:477-87. [PMID: 26641029 DOI: 10.1002/smll.201501985] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
88 Manzini G, Henne-Bruns D, Porzsolt F, Kremer M. Is there a standard for surgical therapy of hepatocellular carcinoma in healthy and cirrhotic liver? BMJ Open Gastroenterol. 2017;4:e000129. [PMID: 28405349 DOI: 10.1136/bmjgast-2016-000129] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
89 Heinz WJ, Kahle K, Helle-beyersdorf A, Schirmer D, Lenker U, Keller D, Langmann P, Klinker H. High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. Cancer Chemother Pharmacol 2011;68:239-45. [DOI: 10.1007/s00280-010-1474-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
90 Huang J, Tian W, Zhang L, Huang Q, Lin S, Ding Y, Liang W, Zheng S. Preoperative Prediction Power of Imaging Methods for Microvascular Invasion in Hepatocellular Carcinoma: A Systemic Review and Meta-Analysis. Front Oncol 2020;10:887. [PMID: 32676450 DOI: 10.3389/fonc.2020.00887] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
91 Meng H, Wang X, Fong Y, Wang ZH, Wang Y, Zhang ZT. Outcomes of radical surgery for gallbladder cancer patients with lymphatic metastases. Jpn J Clin Oncol. 2011;41:992-998. [PMID: 21712255 DOI: 10.1093/jjco/hyr072] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
92 Poruk KE, Pawlik TM, Weiss MJ. Perioperative Management of Hilar Cholangiocarcinoma. J Gastrointest Surg 2015;19:1889-99. [PMID: 26022776 DOI: 10.1007/s11605-015-2854-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
93 Yang J, Wang J, Zhou H, Wang Y, Huang H, Jin H, Lou Q, Shah RJ, Zhang X. Endoscopic radiofrequency ablation plus a novel oral 5-fluorouracil compound versus radiofrequency ablation alone for unresectable extrahepatic cholangiocarcinoma. Gastrointest Endosc 2020;92:1204-1212.e1. [PMID: 32437711 DOI: 10.1016/j.gie.2020.04.075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
94 Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, Imajo K, Aoki Y, Saito H, Kunieda E. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer. 2016;122:2041-2049. [PMID: 27062278 DOI: 10.1002/cncr.30008] [Cited by in Crossref: 96] [Cited by in F6Publishing: 80] [Article Influence: 16.0] [Reference Citation Analysis]
95 Shao GL, Zheng JP, Guo LW, Chen YT, Zeng H, Yao Z. Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging: A prospective study. Medicine (Baltimore) 2017;96:e5518. [PMID: 28099329 DOI: 10.1097/MD.0000000000005518] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Rahnemai-Azar AA, Pandey P, Kamel I, Pawlik TM. Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection. Hepat Oncol 2016;3:223-39. [PMID: 30191045 DOI: 10.2217/hep-2016-0009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
97 Rungsakulkij N, Suragul W, Mingphruedhi S, Tangtawee P, Muangkaew P, Aeesoa S. Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection. World J Clin Cases 2018; 6(6): 110-120 [PMID: 29988930 DOI: 10.12998/wjcc.v6.i6.110] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
98 Deshpande R, O'Reilly D, Sherlock D. Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. Int J Hepatol 2011;2011:686074. [PMID: 21994867 DOI: 10.4061/2011/686074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
99 El Fouly A, Ertle J, El Dorry A, Shaker MK, Dechêne A, Abdella H, Mueller S, Barakat E, Lauenstein T, Bockisch A, Gerken G, Schlaak JF. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int 2015;35:627-35. [DOI: 10.1111/liv.12637] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 7.3] [Reference Citation Analysis]
100 Yin X, Zhang L, Wang YH, Zhang BH, Gan YH, Ge NL, Chen Y, Li LX, Ren ZG. Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma. BMC Cancer. 2014;14:849. [PMID: 25409554 DOI: 10.1186/1471-2407-14-849] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
101 Posadas K, Ankola A, Yang Z, Yee NS. Tumor Molecular Profiling for an Individualized Approach to the Treatment of Hepatocellular Carcinoma: A Patient Case Study. Biomedicines 2018;6:E46. [PMID: 29673151 DOI: 10.3390/biomedicines6020046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
102 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 11.5] [Reference Citation Analysis]
103 Joo I, Choi BI. New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer. 2012;1:94-109. [PMID: 24159577 DOI: 10.1159/000342404] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
104 Blechacz B. Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver. 2017;11:13-26. [PMID: 27928095 DOI: 10.5009/gnl15568] [Cited by in Crossref: 160] [Cited by in F6Publishing: 150] [Article Influence: 32.0] [Reference Citation Analysis]
105 Lee V, Goyal A, Hsu CC, Jacobson JS, Rodriguez RD, Siegel AB. Dietary supplement use among patients with hepatocellular carcinoma. Integr Cancer Ther 2015;14:35-41. [PMID: 25228537 DOI: 10.1177/1534735414550038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
106 Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018;379:54-63. [PMID: 29972759 DOI: 10.1056/NEJMoa1717002] [Cited by in Crossref: 703] [Cited by in F6Publishing: 449] [Article Influence: 175.8] [Reference Citation Analysis]
107 Hatzaras I, Schmidt C, Muscarella P, Melvin WS, Ellison EC, Bloomston M. Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies. HPB (Oxford). 2010;12:134-138. [PMID: 20495658 DOI: 10.1111/j.1477-2574.2009.00149.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
108 Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013;58:2188-97. [PMID: 23512791 DOI: 10.1002/hep.26382] [Cited by in Crossref: 109] [Cited by in F6Publishing: 110] [Article Influence: 12.1] [Reference Citation Analysis]
109 Vinuela E, Vega EA, Yamashita S, Sanhueza M, Mege R, Cavada G, Aloia TA, Chun YS, Lee JE, Vauthey J, Conrad C. Incidental Gallbladder Cancer: Residual Cancer Discovered at Oncologic Extended Resection Determines Outcome: A Report from High- and Low-Incidence Countries. Ann Surg Oncol 2017;24:2334-43. [DOI: 10.1245/s10434-017-5859-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
110 Promraksa B, Katrun P, Phetcharaburanin J, Kittirat Y, Namwat N, Techasen A, Li JV, Loilome W. Metabolic Changes of Cholangiocarcinoma Cells in Response to Coniferyl Alcohol Treatment. Biomolecules 2021;11:476. [PMID: 33810184 DOI: 10.3390/biom11030476] [Reference Citation Analysis]
111 Liu ZY, Tan XY, Li QJ, Liao GC, Fang AP, Zhang DM, Chen PY, Wang XY, Luo Y, Long JA, Zhong RH, Zhu HL. Trimethylamine N-oxide, a gut microbiota-dependent metabolite of choline, is positively associated with the risk of primary liver cancer: a case-control study. Nutr Metab (Lond). 2018;15:81. [PMID: 30479648 DOI: 10.1186/s12986-018-0319-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
112 Jensen EH, Borja-cacho D, Al-refaie WB, Vickers SM. Exocrine Pancreas. Sabiston Textbook of Surgery. Elsevier; 2012. pp. 1515-47. [DOI: 10.1016/b978-1-4377-1560-6.00056-1] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
113 Mantry PS, Mehta A, Madani B, Mejia A, Shahin I. Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. J Gastrointest Oncol 2017;8:799-807. [PMID: 29184683 DOI: 10.21037/jgo.2017.08.03] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
114 Vilarinho S, Taddei T. Therapeutic strategies for hepatocellular carcinoma: new advances and challenges. Curr Treat Options Gastroenterol 2015;13:219-34. [PMID: 25791207 DOI: 10.1007/s11938-015-0049-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
115 Harding JJ. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. Future Oncol 2018;14:2293-302. [PMID: 29663837 DOI: 10.2217/fon-2018-0008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
116 Kim M, Kim IH, Lim MK, Kim Y, Park B. Increased prevalence of metabolic syndrome in adult cancer survivors: Asian first report in community setting. Cancer Epidemiol 2019;58:130-6. [PMID: 30576983 DOI: 10.1016/j.canep.2018.12.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
117 Fang T, Lu Q. A-kinase interacting protein 1 (AKIP1) associates with advanced overall disease condition, tumor properties, and unfavorable prognosis in hepatocellular carcinoma patients. J Clin Lab Anal 2020;34:e23213. [PMID: 32133702 DOI: 10.1002/jcla.23213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
118 Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB, Messino MJ, Holcombe RF, Blanke CD. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol 2011;68:1595-602. [PMID: 21556747 DOI: 10.1007/s00280-011-1657-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
119 Chon YE, Jung KS, Kim MJ, Choi JY, An C, Park JY, Ahn SH, Kim BK, Kim SU, Park H, Hwang SK, Rim KS, Han KH, Kim DY. Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. Aliment Pharmacol Ther 2018;47:1201-12. [PMID: 29492988 DOI: 10.1111/apt.14578] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
120 Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, Goh BK, Wong JS, Tay KH, Goh AS, Yan SX, Loke KS, Thang SP, Gogna A, Too CW, Irani FG, Leong S, Lim KH, Thng CH. National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. Liver Cancer. 2016;5:97-106. [PMID: 27386428 DOI: 10.1159/000367759] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
121 Zhang ZM, Guo JX, Zhang ZC, Jiang N, Zhang ZY, Pan LJ. Therapeutic options for intermediate-advanced hepatocellular carcinoma. World J Gastroenterol 2011;17:1685-9. [PMID: 21483627 DOI: 10.3748/wjg.v17.i13.1685] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
122 Weintraub JL, Salem R. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. J Vasc Interv Radiol. 2013;24:1123-1134. [PMID: 23562168 DOI: 10.1016/j.jvir.2013.01.494] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
123 Bai K, Cao Y, Huang C, Chen J, Zhang X, Jiang Y. Association of Histone Methyltransferase G9a and Overall Survival After Liver Resection of Patients With Hepatocellular Carcinoma With a Median Observation of 40 Months. Medicine (Baltimore) 2016;95:e2493. [PMID: 26765460 DOI: 10.1097/MD.0000000000002493] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
124 Li LQ, Zhao WD, Su TS, Wang YD, Meng WW, Liang SX. Effect of Body Composition on Outcomes in Patients with Hepatocellular Carcinoma Undergoing Radiotherapy: A Retrospective Study. Nutr Cancer 2022;:1-10. [PMID: 35543186 DOI: 10.1080/01635581.2022.2074472] [Reference Citation Analysis]
125 Chen LC, Chiou WY, Lin HY, Lee MS, Lo YC, Huang LW, Chang CM, Hung TH, Lin CW, Tseng KC, Liu DW, Hsu FC, Hung SK. Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial. BMC Cancer 2019;19:275. [PMID: 30922261 DOI: 10.1186/s12885-019-5461-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
126 Kim MJ, Kim SM, Jung HA, Hong JY, Chang WJ, Choi MK, Kim HS, Sun JM, Park K, Ahn MJ. Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Korean J Intern Med 2019;34:1107-15. [PMID: 29914230 DOI: 10.3904/kjim.2017.234] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
127 Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Zhao Y, Hamm B, Gebauer B, Lin M, Geschwind JF, Chapiro J. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. Eur Radiol 2016;26:3243-52. [PMID: 26762942 DOI: 10.1007/s00330-015-4168-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
128 Kanata N, Yoshikawa T, Ohno Y, Kanda T, Uchida K, Izaki K, Fukumoto T, Ku Y, Itoh T, Kitajima K, Takahashi S, Sugimura K. HCC-to-liver contrast on arterial-dominant phase images of EOB-enhanced MRI: comparison with dynamic CT. Magnetic Resonance Imaging 2013;31:17-22. [DOI: 10.1016/j.mri.2012.06.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
129 Simoneau E, Hassanain M, Madkhali A, Salman A, Nudo CG, Chaudhury P, Metrakos P. (18)F-Fluorodeoxyglucose positron-emission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma. Curr Oncol. 2014;21:e551-e556. [PMID: 25089106 DOI: 10.3747/co.21.1959] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
130 Yeh MM, Yeung RS, Apisarnthanarax S, Bhattacharya R, Cuevas C, Harris WP, Hon TLK, Padia SA, Park JO, Riggle KM, Daoud SS. Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol 2015; 7(11): 1460-1483 [PMID: 26085907 DOI: 10.4254/wjh.v7.i11.1460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
131 Zhao J, Zhu XC, Wu XS, Wang L, Zhu CC, Yang K, Deng GQ, Wang A, Liu Y, Jia WD, Zhu L. Identification of miR-4644 as a suitable endogenous normalizer for circulating miRNA quantification in hepatocellular carcinoma. J Cancer 2020;11:7032-44. [PMID: 33123293 DOI: 10.7150/jca.48903] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
132 Zhang P, Wen F, Li Q. FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. Dig Liver Dis. 2016;48:1492-1497. [PMID: 27486048 DOI: 10.1016/j.dld.2016.07.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
133 Liao LE, Hu DD, Zheng Y. A Four-Methylated lncRNAs-Based Prognostic Signature for Hepatocellular Carcinoma. Genes (Basel). 2020;11. [PMID: 32784402 DOI: 10.3390/genes11080908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
134 Zhu AX, Knox JJ. Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues. Oncologist. 2012;17:1504-1507. [PMID: 23220842 DOI: 10.1634/theoncologist.2012-0432] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
135 Wang XY, Fang AP, Chen PY, Liao GC, Zhang YJ, Shivappa N, Hébert JR, Chen YM, Zhu HL. High dietary inflammatory index scores are associated with an elevated risk of hepatocellular carcinoma in a case-control study. Food Funct 2018;9:5832-42. [PMID: 30357201 DOI: 10.1039/c8fo01190g] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
136 Fang A, Liu Z, Liao G, Chen P, Wang X, Zhang D, Luo Y, Long J, Zhong R, Zhou Z, Xu Y, Xu X, Ling W, Chen M, Zhang Y, Zhu H. Serum folate concentrations at diagnosis are associated with hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort study. Br J Nutr 2019;121:1376-88. [DOI: 10.1017/s0007114519000734] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
137 Peng J, Li JJ, Li J, Li HW, Xu GP, Jia RR, Zhang XN, Zhao Y. Could ADC values be a promising diagnostic criterion for differentiating malignant and benign hepatic lesions in Asian populations: A meta-analysis. Medicine (Baltimore) 2016;95:e5470. [PMID: 27902599 DOI: 10.1097/MD.0000000000005470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
138 Krasnick BA, Jin LX, Davidson JT 4th, Sanford DE, Ethun CG, Pawlik TM, Poultsides GA, Tran T, Idrees K, Hawkins WG, Chapman WC, Doyle MBM, Weber SM, Strasberg SM, Salem A, Martin RCG, Isom CA, Scoggins C, Schmidt CR, Shen P, Beal E, Hatzaras I, Shenoy R, Maithel SK, Fields RC. Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium. J Surg Oncol. 2018;117:363-371. [PMID: 29284072 DOI: 10.1002/jso.24836] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
139 Erstad DJ, Tanabe KK. Hepatocellular carcinoma: early-stage management challenges. J Hepatocell Carcinoma 2017;4:81-92. [PMID: 28721349 DOI: 10.2147/JHC.S107370] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
140 Örmeci N. Surveillance of the Patients with High Risk of Hepatocellular Cancer. J Gastrointest Cancer 2017;48:246-9. [PMID: 28634670 DOI: 10.1007/s12029-017-9972-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
141 Kantor O, Baker MS. Hepatocellular Carcinoma: Surgical Management and Evolving Therapies. Cancer Treat Res 2016;168:165-83. [PMID: 29206369 DOI: 10.1007/978-3-319-34244-3_8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
142 Kim HY, Park J, Joo J, Kim H, Woo SM, Lee WJ, Kim C. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma: Outcome of sorafenib therapy in cirrhosis. J Gastroenterol Hepatol 2013;28:1756-61. [DOI: 10.1111/jgh.12310] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
143 Cantaloube M, Castan F, Creoff M, Prunaretty J, Bordeau K, Michalet M, Assenat E, Guiu B, Pageaux GP, Ychou M, Aillères N, Fenoglietto P, Azria D, Riou O. Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4853. [PMID: 34638336 DOI: 10.3390/cancers13194853] [Reference Citation Analysis]
144 Miura T, Suzuki N, Nakamura J, Yamada S, Miura T, Yanagi M, Usuda H, Emura I, Takahashi T. Hepatocellular carcinoma, with portal thrombus after viral eradication, disappeared by 5-fluorouracil and interferon. World J Hepatol 2010; 2(11): 416-418 [PMID: 21173911 DOI: 10.4254/wjh.v2.i11.416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
145 Li D, Kang J, Madoff DC. Locally ablative therapies for primary and metastatic liver cancer. Expert Rev Anticancer Ther. 2014;14:931-945. [PMID: 24746315 DOI: 10.1586/14737140.2014.911091] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
146 Herrmann E, Naehrig D, Sassowsky M, Bigler M, Buijsen J, Ciernik I, Zwahlen D, Pellanda AF, Meister A, Brauchli P, Berardi S, Kuettel E, Dufour JF, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK). External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26. Radiat Oncol 2017;12:12. [PMID: 28086942 DOI: 10.1186/s13014-016-0745-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
147 Shirai Y, Wakai T, Sakata J, Hatakeyama K. Regional lymphadenectomy for gallbladder cancer: Rational extent, technical details, and patient outcomes. World J Gastroenterol 2012; 18(22): 2775-2783 [PMID: 22719185 DOI: 10.3748/wjg.v18.i22.2775] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
148 Zheng T, Chen M, Han S, Zhang L, Bai Y, Fang X, Ding SZ, Yang Y. Plasma minichromosome maintenance complex component 6 is a novel biomarker for hepatocellular carcinoma patients. Hepatol Res. 2014;44:1347-1356. [PMID: 24451028 DOI: 10.1111/hepr.12303] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
149 Ding G, Yang Y, Cao L, Chen W, Wu Z, Jiang G. A modified Jarnagin-Blumgart classification better predicts survival for resectable hilar cholangiocarcinoma. World J Surg Oncol. 2015;13:99. [PMID: 25889726 DOI: 10.1186/s12957-015-0526-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
150 He L, Niu L, Korpan NN, Sumida S, Xiao Y, Li J, Sutedja B, Lu Y, Zuo J, Liu J, Xu K. Clinical Practice Guidelines for Cryosurgery of Pancreatic Cancer: A Consensus Statement From the China Cooperative Group of Cryosurgery on Pancreatic Cancer, International Society of Cryosurgery, and Asian Society of Cryosurgery. Pancreas 2017;46:967-72. [PMID: 28742542 DOI: 10.1097/MPA.0000000000000878] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
151 Hwang JW, Kim H, Lee DJ. The 100 most influential manuscripts on hepatocellular carcinoma: a bibliometric analysis. J Int Med Res 2019;47:1467-82. [PMID: 30890000 DOI: 10.1177/0300060519835974] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
152 Li L, Li X, Zhang Q, Ye T, Zou S, Yan J. EIF5A expression and its role as a potential diagnostic biomarker in hepatocellular carcinoma. J Cancer 2021;12:4774-9. [PMID: 34234848 DOI: 10.7150/jca.58168] [Reference Citation Analysis]
153 Lan QY, Liao GC, Zhou RF, Chen PY, Wang XY, Chen MS, Chen YM, Zhu HL. Dietary patterns and primary liver cancer in Chinese adults: a case-control study. Oncotarget 2018;9:27872-81. [PMID: 29963244 DOI: 10.18632/oncotarget.23910] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
154 Petrou A, Neofytou K, Mihas C, Bagenal J, Kontos M, Griniatsos J, Felekouras E. Radiofrequency ablation-assisted liver resection: a step toward bloodless liver resection. Hepatobiliary Pancreat Dis Int 2015;14:69-74. [PMID: 25655293 DOI: 10.1016/s1499-3872(14)60304-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
155 Gong WF, Zhong JH, Xiang BD, Li LQ. Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy. Mol Clin Oncol 2016;5:3-6. [PMID: 27330754 DOI: 10.3892/mco.2016.871] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
156 Lee SE, Jang JY, Lim CS, Kang MJ, Kim SW. Systematic review on the surgical treatment for T1 gallbladder cancer. World J Gastroenterol 2011; 17(2): 174-180 [PMID: 21245989 DOI: 10.3748/wjg.v17.i2.174] [Cited by in CrossRef: 81] [Cited by in F6Publishing: 71] [Article Influence: 7.4] [Reference Citation Analysis]
157 Goetze TO, Paolucci V. Influence of high- and low-volume liver surgery in gallbladder carcinoma. World J Gastroenterol 2014; 20(48): 18445-18451 [PMID: 25561815 DOI: 10.3748/wjg.v20.i48.18445] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
158 Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.e2. [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049] [Cited by in Crossref: 390] [Cited by in F6Publishing: 366] [Article Influence: 32.5] [Reference Citation Analysis]
159 Padia SA, Alessio A, Kwan SW, Lewis DH, Vaidya S, Minoshima S. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis. J Vasc Interv Radiol 2013;24:1147-53. [PMID: 23792126 DOI: 10.1016/j.jvir.2013.04.018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
160 He Y, Guo Y, Chen J, Hu X, Li X, Kong Y, Zhang X, Zhou X, Liu L, Hou J. Multiple Antigen Stimulating Cellular Therapy (MASCT) For Hepatocellular Carcinoma After Curative Treatment: A Retrospective Study. J Cancer 2018;9:1385-93. [PMID: 29721048 DOI: 10.7150/jca.23725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
161 Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015;6:28453-28462. [PMID: 26164085 DOI: 10.18632/oncotarget.4601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
162 Stroehl YW, Letzen BS, van Breugel JM, Geschwind JF, Chapiro J. Intra-arterial therapies for liver cancer: assessing tumor response. Expert Rev Anticancer Ther 2017;17:119-27. [PMID: 27983883 DOI: 10.1080/14737140.2017.1273775] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
163 Abdalla M, Khairy E, Louka ML, Ali-Labib R, Ibrahim EA. Vitamin D receptor gene methylation in hepatocellular carcinoma. Gene 2018;653:65-71. [PMID: 29432829 DOI: 10.1016/j.gene.2018.02.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
164 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
165 Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. The Lancet Oncology 2017;18:e101-12. [DOI: 10.1016/s1470-2045(16)30569-1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 35] [Article Influence: 12.4] [Reference Citation Analysis]
166 Duan C, Liu M, Zhang Z, Ma K, Bie P. Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis. World J Surg Oncol. 2013;11:190. [PMID: 23941614 DOI: 10.1186/1477-7819-11-190] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
167 Wang XC, Wang F, Quan QQ. Roles of XRCC1/XPD/ERCC1 Polymorphisms in Predicting Prognosis of Hepatocellular Carcinoma in Patients Receiving Transcatheter Arterial Chemoembolization. Genet Test Mol Biomarkers 2016;20:176-84. [PMID: 26918371 DOI: 10.1089/gtmb.2015.0267] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
168 Ladd LM, Tirkes T, Tann M, Agarwal DM, Johnson MS, Tahir B, Sandrasegaran K. Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma. Clin Mol Hepatol 2016;22:450-7. [PMID: 27987537 DOI: 10.3350/cmh.2016.0036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
169 Zhou L, Ji F, Zhang T, Wang F, Li Y, Yu Z, Jin X, Ruan B. An fluorescent aptasensor for sensitive detection of tumor marker based on the FRET of a sandwich structured QDs-AFP-AuNPs. Talanta 2019;197:444-50. [PMID: 30771960 DOI: 10.1016/j.talanta.2019.01.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
170 Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, Kaseb AO, Mcfadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey J, Ghobrial RM. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. The Lancet Gastroenterology & Hepatology 2018;3:337-48. [DOI: 10.1016/s2468-1253(18)30045-1] [Cited by in Crossref: 74] [Cited by in F6Publishing: 33] [Article Influence: 18.5] [Reference Citation Analysis]
171 Liu XR, Cai CX, Luo LM, Zheng WL, Shi R, Zeng J, Xu YQ, Wei M, Ma WL. Decreased expression of Sushi Domain Containing 2 correlates to progressive features in patients with hepatocellular carcinoma. Cancer Cell Int 2016;16:15. [PMID: 26933386 DOI: 10.1186/s12935-016-0286-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
172 Wei W, Liu M, Ning S, Wei J, Zhong J, Li J, Cai Z, Zhang L. Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma. BMC Cancer 2020;20:6. [PMID: 31898536 DOI: 10.1186/s12885-019-6489-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
173 Darnell A, Forner A, Rimola J, Reig M, García-Criado Á, Ayuso C, Bruix J. Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. Radiology. 2015;275:698-707. [PMID: 25658038 DOI: 10.1148/radiol.15141132] [Cited by in Crossref: 97] [Cited by in F6Publishing: 88] [Article Influence: 13.9] [Reference Citation Analysis]
174 Kim DH, Kim SH, Choi GH, Kang CM, Kim KS, Choi JS, Lee WJ. Role of Cholecystectomy and Lymph Node Dissection in Patients with T2 Gallbladder Cancer. World J Surg 2013;37:2635-40. [DOI: 10.1007/s00268-013-2187-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
175 Tong MJ, Rosinski AA, Huynh CT, Raman SS, Lu DSK. Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. Hepatol Commun 2017;1:595-608. [PMID: 29404481 DOI: 10.1002/hep4.1047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
176 Kim HD, Lim YS, Han S, An J, Kim GA, Kim SY, Lee SJ, Won HJ, Byun JH. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival. Gastroenterology. 2015;148:1371-1382. [PMID: 25733098 DOI: 10.1053/j.gastro.2015.02.051] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 9.7] [Reference Citation Analysis]
177 Littau MJ, Kulshrestha S, Bunn C, Kim P, Luchette FA, Baker MS. Is positive histologic surgical margin associated with overall survival in patients with resectable gallbladder cancer? Surg Open Sci 2021;6:15-20. [PMID: 34409279 DOI: 10.1016/j.sopen.2021.07.003] [Reference Citation Analysis]
178 Molvar C, Lewandowski R. Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts. Semin Intervent Radiol 2015;32:388-97. [PMID: 26622103 DOI: 10.1055/s-0035-1564704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
179 Vega EA, De Aretxabala X, Qiao W, Newhook TE, Okuno M, Castillo F, Sanhueza M, Diaz C, Cavada G, Jarufe N, Munoz C, Rencoret G, Vivanco M, Joechle K, Tzeng CD, Vauthey J, Vinuela E, Conrad C. Comparison of oncological outcomes after open and laparoscopic re-resection of incidental gallbladder cancer. British Journal of Surgery 2020;107:289-300. [DOI: 10.1002/bjs.11379] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 6.3] [Reference Citation Analysis]
180 Zhang Y, Desai A, Yang SY, Bae KB, Antczak MI, Fink SP, Tiwari S, Willis JE, Williams NS, Dawson DM, Wald D, Chen WD, Wang Z, Kasturi L, Larusch GA, He L, Cominelli F, Di Martino L, Djuric Z, Milne GL, Chance M, Sanabria J, Dealwis C, Mikkola D, Naidoo J, Wei S, Tai HH, Gerson SL, Ready JM, Posner B, Willson JK, Markowitz SD. TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science 2015;348:aaa2340. [PMID: 26068857 DOI: 10.1126/science.aaa2340] [Cited by in Crossref: 140] [Cited by in F6Publishing: 134] [Article Influence: 20.0] [Reference Citation Analysis]
181 Li K, Su Z, Xu E, Guan P, Li LJ, Zheng R. Computer-Assisted Hepatocellular Carcinoma Ablation Planning Based on 3-D Ultrasound Imaging. Ultrasound Med Biol 2016;42:1951-7. [PMID: 27126243 DOI: 10.1016/j.ultrasmedbio.2016.03.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
182 Wu X, Li B, Qiu J, Shen J, Zheng Y, Li Q, Liao Y, He W, Zou R, Yuan Y. Hepatectomy Versus Hepatectomy With Lymphadenectomy in Hepatocellular Carcinoma: A Prospective, Randomized Controlled Clinical Trial. J Clin Gastroenterol. 2015;49:520-528. [PMID: 25564411 DOI: 10.1097/mcg.0000000000000277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
183 Xu JH, Chang WH, Fu HW, Shu WQ, Yuan T, Chen P. Upregulated long non-coding RNA LOC90784 promotes cell proliferation and invasion and is associated with poor clinical features in HCC. Biochem Biophys Res Commun. 2017;490:920-926. [PMID: 28651931 DOI: 10.1016/j.bbrc.2017.06.141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
184 Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept. J Vasc Interv Radiol. 2018;29:850-857.e1. [PMID: 29548875 DOI: 10.1016/j.jvir.2018.01.769] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 14.0] [Reference Citation Analysis]
185 Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers (Basel) 2020;12:E1914. [PMID: 32679897 DOI: 10.3390/cancers12071914] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
186 Chapiro J, Duran R, Geschwind JF. Combination of intra-arterial therapies and sorafenib: is there a clinical benefit? Radiol Med 2014;119:476-82. [PMID: 24894921 DOI: 10.1007/s11547-014-0413-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
187 Yang S, Zhang B, Gong X, Wang T, Liu Y, Zhang N. In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer. Int J Nanomedicine 2016;11:2329-43. [PMID: 27307733 DOI: 10.2147/IJN.S104119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
188 Yi HK, Park YJ, Bae JH, Lee JK, Lee KH, Choi SH, Lee KH, Kim BT, Choi JY. Inverse Prognostic Relationships of 18F-FDG PET/CT Metabolic Parameters in Patients with Distal Bile Duct Cancer Undergoing Curative Surgery. Nucl Med Mol Imaging 2018;52:334-41. [PMID: 30344781 DOI: 10.1007/s13139-018-0542-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
189 Zhang D, Luo Y, Yishake D, Liu Z, He T, Luo Y, Zhang Y, Fang A, Zhu H. Prediagnostic dietary intakes of vitamin A and β-carotene are associated with hepatocellular-carcinoma survival. Food Funct 2020;11:759-67. [DOI: 10.1039/c9fo02468a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
190 Yeo W, Chen PJ, Furuse J, Han KH, Hsu C, Lim HY, Moon H, Qin S, Yeoh EM, Ye SL. Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. BMC Cancer 2010;10:620. [PMID: 21062497 DOI: 10.1186/1471-2407-10-620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
191 Qu KZ, Zhang K, Ma W, Li H, Wang X, Zhang X, Giles F, Lai M, Afdhal NH, Albitar M. Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease: Serum proteasomes and hepatocellular cancer. Journal of Gastroenterology and Hepatology 2011;26:751-8. [DOI: 10.1111/j.1440-1746.2010.06491.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
192 Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015;5:1040-1048. [PMID: 26109333 DOI: 10.1158/2159-8290.cd-15-0274.cell-free] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
193 Lea WB, Tapp KN, Tann M, Hutchins GD, Fletcher JW, Johnson MS. Microsphere Localization and Dose Quantification Using Positron Emission Tomography/CT following Hepatic Intraarterial Radioembolization with Yttrium-90 in Patients with Advanced Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2014;25:1595-603. [DOI: 10.1016/j.jvir.2014.06.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
194 Lee YG, Han SW, Oh DY, Chie EK, Jang JY, Im SA, Kim TY, Kim SW, Ha SW, Bang YJ. Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection. BMC Cancer 2011;11:188. [PMID: 21599995 DOI: 10.1186/1471-2407-11-188] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
195 Liu ZY, Zhang DM, Yishake D, Luo Y, Fang AP, Zhu HL. Dietary choline, rather than betaine intake, is associated with hepatocellular carcinoma mortality. Food Funct 2020;11:7866-77. [PMID: 32812611 DOI: 10.1039/d0fo01890b] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
196 Yang X, Ye X, Sun L, Gao F, Li Y, Ji X, Wang X, Feng Y, Wang X. Downregulation of serum RAB27B confers improved prognosis and is associated with hepatocellular carcinoma progression through PI3K-AKT-P21 signaling. Oncotarget 2017;8:61118-32. [PMID: 28977851 DOI: 10.18632/oncotarget.18010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
197 Sangro B. Evidence-based integration of selective internal radiation therapy into hepatocellular carcinoma management. Future Oncol 2014;10:7-11. [PMID: 25478760 DOI: 10.2217/fon.14.216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
198 Ettrich TJ, Schwerdel D, Dolnik A, Beuter F, Blätte TJ, Schmidt SA, Stanescu-Siegmund N, Steinacker J, Marienfeld R, Kleger A, Bullinger L, Seufferlein T, Berger AW. Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information. Sci Rep 2019;9:13261. [PMID: 31519967 DOI: 10.1038/s41598-019-49860-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
199 Jin LX, Pitt SC, Hall BL, Pitt HA. Aggressive surgical management of gallbladder cancer: at what cost? Surgery. 2013;154:266-273. [PMID: 23830031 DOI: 10.1016/j.surg.2013.04.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
200 Ahn SH, Kim SH, Choi GH, Choi JS, Kim KS. The optimal follow-up period in patients with above 5-year disease-free survival after curative liver resection for hepatocellular carcinoma. J Korean Surg Soc 2013;85:269-74. [PMID: 24368984 DOI: 10.4174/jkss.2013.85.6.269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
201 Sorin Y, Ikeda K, Kawamura Y, Fujiyama S, Kobayashi M, Hosaka T, Sezaki H, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study. Liver Cancer 2018;7:323-34. [PMID: 30488022 DOI: 10.1159/000487311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
202 Hernandez JM, Elahi A, Clark CW, Wang J, Humphries LA, Centeno B, Bloom G, Fuchs BC, Yeatman T, Shibata D. miR-675 Mediates Downregulation of Twist1 and Rb in AFP-Secreting Hepatocellular Carcinoma. Ann Surg Oncol 2013;20:625-35. [DOI: 10.1245/s10434-013-3106-3] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 6.0] [Reference Citation Analysis]
203 Kim MU, Kim HC, Chung JW, An S, Seong NJ, Jae HJ, Park JH. Hepatocellular carcinoma: prediction of blood supply from an intercostal artery with multidetector row computed tomography. J Vasc Interv Radiol. 2011;22:1403-1408. e1. [PMID: 21763155 DOI: 10.1016/j.jvir.2011.05.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
204 Ruman U, Buskaran K, Pastorin G, Masarudin MJ, Fakurazi S, Hussein MZ. Synthesis and Characterization of Chitosan-Based Nanodelivery Systems to Enhance the Anticancer Effect of Sorafenib Drug in Hepatocellular Carcinoma and Colorectal Adenocarcinoma Cells. Nanomaterials (Basel) 2021;11:497. [PMID: 33669332 DOI: 10.3390/nano11020497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
205 Liu ZY, Yishake D, Fang AP, Zhang DM, Liao GC, Tan XY, Zhang YJ, Zhu HL. Serum choline is associated with hepatocellular carcinoma survival: a prospective cohort study. Nutr Metab (Lond) 2020;17:25. [PMID: 32256673 DOI: 10.1186/s12986-020-00445-z] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
206 Lopez-aguiar AG, Ethun CG, Mcinnis MR, Pawlik TM, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal EW, Hatzaras I, Shenoy R, Cardona K, Maithel SK. Association of perioperative transfusion with survival and recurrence after resection of gallbladder cancer: A 10-institution study from the US Extrahepatic Biliary Malignancy Consortium. J Surg Oncol 2018;117:1638-47. [DOI: 10.1002/jso.25086] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
207 Yi X, Long X, Zai H, Xiao D, Li W, Li Y. Unsuspected gallbladder carcinoma discovered during or after cholecystectomy: focus on appropriate radical re-resection according to the T-stage. Clin Transl Oncol. 2013;15:652-658. [PMID: 23359177 DOI: 10.1007/s12094-012-0988-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
208 Lee H, Kwon W, Han Y, Kim JR, Kim S, Jang J. Optimal extent of surgery for early gallbladder cancer with regard to long-term survival: a meta-analysis. J Hepatobiliary Pancreat Sci 2018;25:131-41. [DOI: 10.1002/jhbp.521] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
209 Shun SC, Chen CH, Sheu JC, Liang JD, Yang JC, Lai YH. Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. Oncologist. 2012;17:732-739. [PMID: 22511265 DOI: 10.1634/theoncologist.2011-0368] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
210 Zhang Y, Li Y, Ji H, Zhao X, Lu H. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis. Biosci Trends 2015;9:289-98. [PMID: 26559021 DOI: 10.5582/bst.2015.01089] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
211 Blüthner E, Jara M, Shrestha R, Faber W, Pratschke J, Stockmann M, Malinowski M. Future liver remnant function as a predictor of postoperative morbidity following liver resection for hepatocellular carcinoma - A risk factor analysis. Surg Oncol 2020;33:257-65. [PMID: 32561090 DOI: 10.1016/j.suronc.2020.02.004] [Reference Citation Analysis]
212 Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol. 2014;25:1067-1073. [PMID: 24837982 DOI: 10.1016/j.jvir.2014.03.030] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
213 Ho EY, Cozen ML, Shen H, Lerrigo R, Trimble E, Ryan JC, Corvera CU, Monto A; HOVAS Group (Hepatocellular Carcinoma Treatment Outcome at VA San Francisco). Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. HPB (Oxford). 2014;16:758-767. [PMID: 24467780 DOI: 10.1111/hpb.12214] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
214 Liu GJ, Li XH, Chen YX, Sun HD, Zhao GM, Hu SY. Radical lymph node dissection and assessment: Impact on gallbladder cancer prognosis. World J Gastroenterol 2013; 19(31): 5150-5158 [PMID: 23964151 DOI: 10.3748/wjg.v19.i31.5150] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
215 Shirai Y, Sakata J, Wakai T, Ohashi T, Hatakeyama K. "Extended" radical cholecystectomy for gallbladder cancer: Long-term outcomes, indications and limitations. World J Gastroenterol 2012; 18(34): 4736-4743 [PMID: 23002343 DOI: 10.3748/wjg.v18.i34.4736] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
216 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 251] [Article Influence: 30.9] [Reference Citation Analysis]
217 Kim HY, Park JW. Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer. 2014;3:9-17. [PMID: 24804173 DOI: 10.1159/000343854] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
218 Cheon J, Chon HJ, Bang Y, Park NH, Shin JW, Kim KM, Lee HC, Lee J, Yoo C, Ryoo BY. Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. Liver Cancer 2020;9:613-24. [PMID: 33083284 DOI: 10.1159/000508901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
219 Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 2012;32:1053-1063. [PMID: 22432445 DOI: 10.1111/j.1478-3231.2012.02792.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
220 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
221 Yishake D, He TT, Liu ZY, Chen S, Luo Y, Liu XZ, Huang RZ, Lan QY, Fang AP, Zhu HL. Dietary protein and prognosis of hepatocellular carcinoma: a prospective cohort study. Food Funct 2021;12:11568-76. [PMID: 34709274 DOI: 10.1039/d1fo02013g] [Reference Citation Analysis]
222 La Gamma N, Nandakumar G. The management of gastrointestinal tract malignancies. Hosp Pract (1995) 2013;41:7-15. [PMID: 23545755 DOI: 10.3810/hp.2013.04.1021] [Reference Citation Analysis]
223 Renzulli M, Tovoli F, Clemente A, Ierardi AM, Pettinari I, Peta G, Marasco G, Festi D, Piscaglia F, Cappabianca S, Carrafiello G, Golfieri R. Ablation for hepatocellular carcinoma: beyond the standard indications. Med Oncol 2020;37:23. [PMID: 32166482 DOI: 10.1007/s12032-020-01348-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
224 Li J, Qiyu S, Wang T, Jin B, Li N. Improving the Detection of Hepatocellular Carcinoma Using Serum AFP Expression in Combination with GPC3 and Micro-RNA MiR-122 Expression. Open Life Sci 2019;14:53-61. [PMID: 33817137 DOI: 10.1515/biol-2019-0007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
225 Gao S, Xu X, Wang Y, Zhang W, Wang X. Diagnostic utility of plasma lncRNA small nucleolar RNA host gene 1 in patients with hepatocellular carcinoma. Mol Med Rep 2018;18:3305-13. [PMID: 30066898 DOI: 10.3892/mmr.2018.9336] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
226 Hsu C, Chen BB, Chen CH, Ho MC, Cheng JC, Kokudo N, Murakami T, Yeo W, Seong J, Jia JD. Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer. 2015;4:96-105. [PMID: 26020032 DOI: 10.1159/000367732] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
227 Vega EA, Mellado S, Salehi O, Freeman R, Conrad C. Treatment of Resectable Gallbladder Cancer. Cancers 2022;14:1413. [DOI: 10.3390/cancers14061413] [Reference Citation Analysis]
228 Shah C, Mramba LK, Bishnoi R, Bejjanki H, Chhatrala HS, Chandana SR. Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: pre and post sorafenib era. J Gastrointest Oncol 2017;8:789-98. [PMID: 29184682 DOI: 10.21037/jgo.2017.06.16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
229 Zheng J, Chapman WC, Turcotte S, Koerkamp BG, Lee SY, Jarnagin WR. Response to the Comment on "Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in Aninternational Cohort". Ann Surg 2019;269:e34-5. [PMID: 30724808 DOI: 10.1097/SLA.0000000000002871] [Reference Citation Analysis]
230 Luo P, Wu S, Yu Y, Ming X, Li S, Zuo X, Tu J. Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Pathol Oncol Res. 2020;26:599-603. [PMID: 30661224 DOI: 10.1007/s12253-019-00585-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
231 Li WF, Yen YH, Liu YW, Wang CC, Yong CC, Lin CC. Preoperative predictors of non-transplantable recurrence after resection for early-stage hepatocellular carcinoma: application in an East Asian cohort. Updates Surg 2022. [PMID: 35023038 DOI: 10.1007/s13304-021-01220-2] [Reference Citation Analysis]
232 Zhou RF, Chen XL, Zhou ZG, Zhang YJ, Lan QY, Liao GC, Chen YM, Zhu HL. Higher dietary intakes of choline and betaine are associated with a lower risk of primary liver cancer: a case-control study. Sci Rep 2017;7:679. [PMID: 28386093 DOI: 10.1038/s41598-017-00773-w] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
233 Rim CH, Park S, Woo JY, Seong J. Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer. Strahlenther Onkol 2018;194:1017-29. [PMID: 30105451 DOI: 10.1007/s00066-018-1342-y] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
234 Labadie KP, Schaub SK, Khorsand D, Johnson G, Apisarnthanarax S, Park JO. Multidisciplinary approach for multifocal, bilobar hepatocellular carcinoma: A case report and literature review. World J Hepatol 2019; 11(1): 119-126 [PMID: 30705724 DOI: 10.4254/wjh.v11.i1.119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
235 Hu H, Xu L, Chen Y, Luo SJ, Wu YZ, Xu SH, Liu MT, Lin F, Mei Y, Yang Q, Qiang YY, Lin YW, Deng YJ, Lin T, Sha YQ, Huang BJ, Zhang SJ. The Upregulation of Trophinin-Associated Protein (TROAP) Predicts a Poor Prognosis in Hepatocellular Carcinoma. J Cancer 2019;10:957-67. [PMID: 30854102 DOI: 10.7150/jca.26666] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
236 Zhang C, Song Z, Yu G. High expression of Parkin predicts easier recurrence of patients with adjuvant transarterial chemoembolization. Biomarkers in Medicine 2017;11:823-34. [DOI: 10.2217/bmm-2017-0129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
237 Augustyn A, Peng L, Singal AG, Yopp AC. Surveillance for hepatocellular carcinoma secondary to cardiogenic cirrhosis in patients with congenital heart disease. Clin Res Cardiol 2015;104:446-9. [PMID: 25875944 DOI: 10.1007/s00392-015-0809-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
238 Wang Y, Cui W, Fan W, Zhang Y, Yao W, Huang K, Li J. Percutaneous intraductal radiofrequency ablation in the management of unresectable Bismuth types III and IV hilar cholangiocarcinoma. Oncotarget 2016;7:53911-20. [PMID: 27322076 DOI: 10.18632/oncotarget.10116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
239 Song T, Wang L, Su B, Zeng W, Jiang T, Zhang T, Sun G, Wu H. Diagnostic value of alpha-fetoprotein, Lens culinaris agglutinin-reactive alpha-fetoprotein, and des-gamma-carboxyprothrombin in hepatitis B virus-related hepatocellular carcinoma. J Int Med Res 2020;48:300060519889270. [PMID: 31852373 DOI: 10.1177/0300060519889270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
240 Zhang A, Yin C, Wang Z, Zhang Y, Zhao Y, Li A, Sun H, Lin D, Li N. Development and application of a fluorescence protein microarray for detecting serum alpha-fetoprotein in patients with hepatocellular carcinoma. J Int Med Res 2016;44:1414-23. [PMID: 27885040 DOI: 10.1177/0300060516672370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
241 Shen J, Wang A, Wang Q, Gurvich I, Siegel AB, Remotti H, Santella RM. Exploration of genome-wide circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a potential biomarker. Cancer Epidemiol Biomarkers Prev. 2013;22:2364-2373. [PMID: 24127413 DOI: 10.1158/1055-9965.epi-13-0237] [Cited by in Crossref: 72] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
242 Ciurea AM, Vere CC, Schenker M, Gheonea IA, Streba L, Săndulescu LD, Mehedinţeanu AM, Gheonea DI. Evaluation of Hepatocellular Carcinoma Patients: Interim Analysis of Cases from a Tertiary Referral Center in Craiova, Romania. Curr Health Sci J 2021;47:10-5. [PMID: 34211741 DOI: 10.12865/CHSJ.47.01.02] [Reference Citation Analysis]
243 Kodama T, Newberg JY, Kodama M, Rangel R, Yoshihara K, Tien JC, Parsons PH, Wu H, Finegold MJ, Copeland NG, Jenkins NA. Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma. Proc Natl Acad Sci U S A 2016;113:E3384-93. [PMID: 27247392 DOI: 10.1073/pnas.1606876113] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
244 Mu W, Hu C, Zhang H, Qu Z, Cen J, Qiu Z, Li C, Ren H, Li Y, He X, Shi X, Hui L. miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015;25:477-95. [PMID: 25698578 DOI: 10.1038/cr.2015.23] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 7.1] [Reference Citation Analysis]
245 Yokoo T, Patel AD, Lev-Cohain N, Singal AG, Yopp AC, Pedrosa I. Extrahepatic metastasis risk of hepatocellular carcinoma based on α-fetoprotein and tumor staging parameters at cross-sectional imaging. Cancer Manag Res 2017;9:503-11. [PMID: 29081671 DOI: 10.2147/CMAR.S147097] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
246 Cruite I, Tang A, Sirlin CB. Imaging-based diagnostic systems for hepatocellular carcinoma. AJR Am J Roentgenol. 2013;201:41-55. [PMID: 23789657 DOI: 10.2214/ajr.13.10570] [Cited by in Crossref: 52] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
247 Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer. 2013;2:31-39. [PMID: 24159594 DOI: 10.1159/000346220] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
248 Liu D, Chan AC, Fong DY, Lo CM, Khong PL. Evidence-Based Surveillance Imaging Schedule After Liver Transplantation for Hepatocellular Carcinoma Recurrence. Transplantation. 2017;101:107-111. [PMID: 28009758 DOI: 10.1097/tp.0000000000001513] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
249 Gavriilidis P, Askari A, Roberts KJ, Sutcliffe RP. Appraisal of the current guidelines for management of cholangiocarcinoma-using the Appraisal of Guidelines Research and Evaluation II (AGREE II) Instrument. Hepatobiliary Surg Nutr 2020;9:126-35. [PMID: 32355672 DOI: 10.21037/hbsn.2019.09.06] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
250 Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma. J Vis Exp. 2018;. [PMID: 30371657 DOI: 10.3791/58382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
251 Miki D, Ochi H, Hayes CN, Aikata H, Chayama K. Hepatocellular carcinoma: towards personalized medicine. Cancer Sci. 2012;103:846-850. [PMID: 22339805 DOI: 10.1111/j.1349-7006.2012.02242.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
252 Sharma R, Gibbs JF. Recent advances in the management of primary hepatic tumors refinement of surgical techniques and effect on outcome. J Surg Oncol 2010;101:745-54. [DOI: 10.1002/jso.21506] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
253 D'Avola D, Granito A, de la Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma. J Hepatol 2021:S0168-8278(21)02185-1. [PMID: 34793869 DOI: 10.1016/j.jhep.2021.11.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Wang J, Li J, Tang G, Tian Y, Su S, Li Y. Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma. Oncol Lett 2021;21:279. [PMID: 33732355 DOI: 10.3892/ol.2021.12540] [Reference Citation Analysis]
255 Sohal DP, Sun W. Hepatocellular carcinoma: prevention and therapy. Curr Oncol Rep. 2011;13:186-194. [PMID: 21409527 DOI: 10.1007/s11912-011-0165-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
256 Tovoli F, Negrini G, Bolondi L. Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. Hepat Oncol 2016;3:119-36. [PMID: 30191033 DOI: 10.2217/hep-2015-0006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
257 Messina C, Merz V, Frisinghelli M, Trentin C, Grego E, Veccia A, Salati M, Messina M, Carnaghi C, Caffo O. Adjuvant chemotherapy in resected bile duct cancer: A systematic review and meta-analysis of randomized trials. Crit Rev Oncol Hematol. 2019;143:124-129. [PMID: 31563828 DOI: 10.1016/j.critrevonc.2019.09.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
258 Madkhali AA, Fadel ZT, Aljiffry MM, Hassanain MM. Surgical treatment for hepatocellular carcinoma. Saudi J Gastroenterol. 2015;21:11-17. [PMID: 25672233 DOI: 10.4103/1319-3767.151216] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
259 Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA: A Cancer Journal for Clinicians 2012;62:394-9. [DOI: 10.3322/caac.21161] [Cited by in Crossref: 498] [Cited by in F6Publishing: 533] [Article Influence: 49.8] [Reference Citation Analysis]
260 Chapiro J, Lin M, Duran R, Schernthaner RE, Geschwind JF. Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI. Expert Rev Anticancer Ther 2015;15:199-205. [PMID: 25371052 DOI: 10.1586/14737140.2015.978861] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
261 Xia YQ, Hua RJ, Juan C, Zhong ZH, Tao CS, Fang R, Lin H, Rui G, Yong C. SIRT6 Depletion Sensitizes Human Hepatoma Cells to Chemotherapeutics by Downregulating MDR1 Expression. Front Pharmacol 2018;9:194. [PMID: 29563873 DOI: 10.3389/fphar.2018.00194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
262 Kim YC, Kim YH, Um SH, Seo YS, Park EK, Oh SY, Han YM, Choe JG. Usefulness of Bremsstrahlung Images after Intra-arterial Y-90 Resin Microphere Radioembolization for Hepatic Tumors. Nucl Med Mol Imaging. 2011;45:59-67. [PMID: 24899979 DOI: 10.1007/s13139-010-0066-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
263 Vega EA, Vinuela E, Yamashita S, Sanhueza M, Cavada G, Diaz C, Aloia TA, Chun YS, Tzeng CD, Okuno M, Goumard C, Vauthey J, Lee JE, Conrad C. Extended Lymphadenectomy Is Required for Incidental Gallbladder Cancer Independent of Cystic Duct Lymph Node Status. J Gastrointest Surg 2018;22:43-51. [DOI: 10.1007/s11605-017-3507-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
264 Clark T, Maximin S, Meier J, Pokharel S, Bhargava P. Hepatocellular Carcinoma: Review of Epidemiology, Screening, Imaging Diagnosis, Response Assessment, and Treatment. Curr Probl Diagn Radiol. 2015;44:479-486. [PMID: 25979220 DOI: 10.1067/j.cpradiol.2015.04.004] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 11.4] [Reference Citation Analysis]
265 Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683-691. [PMID: 9250266 DOI: 10.1097/md.0000000000003185] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
266 Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459-1476. [PMID: 23306849 DOI: 10.1007/s10620-012-2525-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
267 Lee HC. Noninvasive diagnostic criteria for hepatocellular carcinoma. Clin Mol Hepatol 2012;18:174-7. [PMID: 22893867 DOI: 10.3350/cmh.2012.18.2.174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
268 Eltabbakh M, Zaghla H, Abdel-Razek W, Elshinnawy H, Ezzat S, Gomaa A, Waked I. Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. Med Oncol 2015;32:432. [PMID: 25502085 DOI: 10.1007/s12032-014-0432-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
269 Feng JW, Yang XH, Liu CW, Wu BQ, Sun DL, Chen XM, Jiang Y, Qu Z. Comparison of Laparoscopic and Open Approach in Treating Gallbladder Cancer. J Surg Res. 2019;234:269-276. [PMID: 30527484 DOI: 10.1016/j.jss.2018.09.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
270 Bowen SR, Chapman TR, Borgman J, Miyaoka RS, Kinahan PE, Liou IW, Sandison GA, Vesselle HJ, Nyflot MJ, Apisarnthanarax S. Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients. EJNMMI Res. 2016;6:57. [PMID: 27349530 DOI: 10.1186/s13550-016-0212-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
271 Weatherall TJ, Fenton M, Munene G, Dickson PV, Deneve JL. Locally Advanced, Unresectable Squamous Cell Carcinoma of the Gallbladder. Case Rep Surg. 2015;2015:424650. [PMID: 26236536 DOI: 10.1155/2015/424650] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
272 Han NY, Park BJ, Sung DJ, Kim MJ, Cho SB, Kim DS, Lee JH. Colloid carcinoma of the extrahepatic biliary tract with metastatic lymphadenopathy mimicking cystic neoplasm: a case report. Iran J Radiol 2013;10:90-3. [PMID: 24046786 DOI: 10.5812/iranjradiol.7234] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
273 Pouya FD, Rasmi Y, Camci IY, Tutar Y, Nemati M. Performance of capecitabine in novel combination therapies in colorectal cancer. J Chemother 2021;:1-15. [PMID: 34019782 DOI: 10.1080/1120009X.2021.1920247] [Reference Citation Analysis]
274 Willatt J, Ruma JA, Azar SF, Dasika NL, Syed F. Imaging of hepatocellular carcinoma and image guided therapies - how we do it. Cancer Imaging 2017;17:9. [PMID: 28259177 DOI: 10.1186/s40644-017-0110-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
275 Wu B, Shen Y, Chen X, Wang X, Zhong Z. Effect of lymphadenectomy on the prognosis for N0 gallbladder carcinoma patients: A study based on SEER database. Cancer Med 2021;10:7136-43. [PMID: 34519168 DOI: 10.1002/cam4.4250] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
276 Zhao C, Nguyen MH. Hepatocellular Carcinoma Screening and Surveillance: Practice Guidelines and Real-Life Practice. J Clin Gastroenterol. 2016;50:120-133. [PMID: 26583266 DOI: 10.1097/mcg.0000000000000446] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
277 Kim SH, Jung D, Ahn JH, Kim KS. Differentiation between gallbladder cancer with acute cholecystitis: Considerations for surgeons during emergency cholecystectomy, a cohort study. Int J Surg 2017;45:1-7. [PMID: 28716660 DOI: 10.1016/j.ijsu.2017.07.046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
278 Bae SY, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Yoo BC. Comparison of usefulness of clinical diagnostic criteria for hepatocellular carcinoma in a hepatitis B endemic area. Clin Mol Hepatol 2012;18:185-94. [PMID: 22893869 DOI: 10.3350/cmh.2012.18.2.185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
279 Khan S, Beard RE, Kingham PT, Fong Y, Boerner T, Martinie JB, Vrochides D, Buell JF, Berber E, Kahramangil B, Troisi RI, Vanlander A, Molinari M, Tsung A. Long-Term Oncologic Outcomes Following Robotic Liver Resections for Primary Hepatobiliary Malignancies: A Multicenter Study. Ann Surg Oncol. 2018;25:2652-2660. [PMID: 29987604 DOI: 10.1245/s10434-018-6629-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
280 Zhang R, Lin HM, Cai ZX, Du SJ, Zeng H, Xu LB, Wang J, Liu C. Clinical strategies for differentiating IgG4-related cholecystitis from gallbladder carcinoma to avoid unnecessary surgical resection. Sci China Life Sci. 2020;63:764-770. [PMID: 31321666 DOI: 10.1007/s11427-019-9539-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
281 Vega EA, Sanhueza M, Viñuela E. Minimally Invasive Surgery for Gallbladder Cancer. Surgical Oncology Clinics of North America 2019;28:243-53. [DOI: 10.1016/j.soc.2018.11.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
282 Li WF, Yen YH, Liu YW, Wang CC, Yong CC, Lin CC, Cheng YF, Wang JH, Lu SN. Preoperative predictors of early recurrence after resection for hepatocellular carcinoma. Am J Surg 2021:S0002-9610(21)00471-2. [PMID: 34399978 DOI: 10.1016/j.amjsurg.2021.08.012] [Reference Citation Analysis]
283 Bitzer M, Voesch S, Albert J, Bartenstein P, Bechstein W, Blödt S, Brunner T, Dombrowski F, Evert M, Follmann M, La Fougère C, Freudenberger P, Geier A, Gkika E, Götz M, Hammes E, Helmberger T, Hoffmann RT, Hofmann WP, Huppert P, Kautz A, Knötgen G, Körber J, Krug D, Lammert F, Lang H, Langer T, Lenz P, Mahnken A, Meining A, Micke O, Nadalin S, Nguyen HP, Ockenga J, Oldhafer K, Paprottka P, Paradies K, Pereira P, Persigehl T, Plauth M, Plentz R, Pohl J, Riemer J, Reimer P, Ringwald J, Ritterbusch U, Roeb E, Schellhaas B, Schirmacher P, Schmid I, Schuler A, von Schweinitz D, Seehofer D, Sinn M, Stein A, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Tholen R, Vogel A, Vogl T, Vorwerk H, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wittekind C, Wörns MA, Galle P, Malek N. S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome. Z Gastroenterol 2022;60:e186-227. [PMID: 35148560 DOI: 10.1055/a-1589-7854] [Reference Citation Analysis]
284 Lee S, Choi KD, Hong SM, Park SH, Gong EJ, Na HK, Ahn JY, Jung KW, Lee JH, Kim DH, Song HJ, Lee GH, Jung HY, Kim JH. Pattern of extragastric recurrence and the role of abdominal computed tomography in surveillance after endoscopic resection of early gastric cancer: Korean experiences. Gastric Cancer 2017;20:843-52. [PMID: 28130712 DOI: 10.1007/s10120-017-0691-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
285 Elsayes KM, Hooker JC, Agrons MM, Kielar AZ, Tang A, Fowler KJ, Chernyak V, Bashir MR, Kono Y, Do RK, Mitchell DG, Kamaya A, Hecht EM, Sirlin CB. 2017 Version of LI-RADS for CT and MR Imaging: An Update. Radiographics. 2017;37:1994-2017. [PMID: 29131761 DOI: 10.1148/rg.2017170098] [Cited by in Crossref: 124] [Cited by in F6Publishing: 121] [Article Influence: 31.0] [Reference Citation Analysis]
286 Zhou DY, Qin J, Huang J, Wang F, Xu GP, Lv YT, Zhang JB, Shen LM. Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models. Oncol Lett 2017;14:4078-84. [PMID: 28943915 DOI: 10.3892/ol.2017.6717] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
287 Kim BK, Park JY, Choi HJ, Kim DY, Ahn SH, Kim JK, Lee DY, Lee KH, Han KH. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2011;137:659-667. [PMID: 20552225 DOI: 10.1007/s00432-010-0917-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
288 Ge T, Shen Q, Wang N, Zhang Y, Ge Z, Chu W, Lv X, Zhao F, Zhao W, Fan J, Qin W. Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma. Med Oncol 2015;32. [DOI: 10.1007/s12032-014-0367-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
289 Cai YL, Song PP, Tang W, Cheng NS. An updated systematic review of the evolution of ALPPS and evaluation of its advantages and disadvantages in accordance with current evidence. Medicine (Baltimore). 2016;95:e3941. [PMID: 27311006 DOI: 10.1097/md.0000000000003941] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
290 Hyder O, Dodson RM, Sachs T, Weiss M, Mayo SC, Choti MA, Wolfgang CL, Herman JM, Pawlik TM. Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: a propensity score-matched Surveillance, Epidemiology, and End Results analysis. Surgery. 2014;155:85-93. [PMID: 23876364 DOI: 10.1016/j.surg.2013.06.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
291 Goetze TO. Gallbladder carcinoma: Prognostic factors and therapeutic options. World J Gastroenterol 2015; 21(43): 12211-12217 [PMID: 26604631 DOI: 10.3748/wjg.v21.i43.12211] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 78] [Article Influence: 13.4] [Reference Citation Analysis]
292 Jusufi MS, Makridis G, Feyerabend B, Oldhafer KJ. First Report of a Late Lethal Pulmonary Biliary Embolism following Hepatic Microwave Ablation. Visc Med 2021;37:550-4. [PMID: 35087904 DOI: 10.1159/000511932] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
293 Li WF, Yen YH, Liu YW, Wang CC, Yong CC, Lin CC, Cheng YF, Wang JH. Validation of an alpha-fetoprotein model to predict recurrence after liver resection for hepatocellular carcinoma. Updates Surg 2021. [PMID: 34374920 DOI: 10.1007/s13304-021-01147-8] [Reference Citation Analysis]
294 Patt Y, Rojas-Hernandez C, Fekrazad HM, Bansal P, Lee FC. Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20. Oncologist 2017;22:1158-e116. [PMID: 28687627 DOI: 10.1634/theoncologist.2017-0168] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
295 Xu G, Qi FZ, Zhang JH, Cheng GF, Cai Y, Miao Y. Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. World J Surg Oncol. 2012;10:163. [PMID: 22897815 DOI: 10.1186/1477-7819-10-163] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
296 Jung W, Jang JY, Kang MJ, Chang YR, Shin YC, Chang J, Kim SW. Effects of Surgical Methods and Tumor Location on Survival and Recurrence Patterns after Curative Resection in Patients with T2 Gallbladder Cancer. Gut Liver 2016;10:140-6. [PMID: 26347513 DOI: 10.5009/gnl15080] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
297 Lee YK, Kim SU, Kim do Y, Ahn SH, Lee KH, Lee do Y, Han KH, Chon CY, Park JY. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer. 2013;13:5. [PMID: 23282286 DOI: 10.1186/1471-2407-13-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
298 Tran TB, Nissen NN. Surgery for gallbladder cancer in the US: a need for greater lymph node clearance. J Gastrointest Oncol. 2015;6:452-458. [PMID: 26487937 DOI: 10.3978/j.issn.2078-6891.2015.062] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
299 Geschwind JF, Gholam PM, Goldenberg A, Mantry P, Martin RC, Piperdi B, Zigmont E, Imperial J, Babajanyan S, Foreman PK, Cohn A. Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry. Liver Cancer 2016;5:37-46. [PMID: 26989658 DOI: 10.1159/000367757] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
300 Duan F, Wang MQ, Liu FY, Wang ZJ, Song P, Wang Y. Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis. Asia Pac J Clin Oncol. 2012;8:156-163. [PMID: 22524574 DOI: 10.1111/j.1743-7563.2012.01542.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
301 Zhao R, Wu Y, Wang T, Zhang Y, Kong D, Zhang L, Li X, Wang G, Jin Y, Jin X, Zhang F. Elevated Src expression associated with hepatocellular carcinoma metastasis in northern Chinese patients. Oncol Lett 2015;10:3026-34. [PMID: 26722284 DOI: 10.3892/ol.2015.3706] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
302 Lee GC, Ferrone CR, Tanabe KK, Lillemoe KD, Blaszkowsky LS, Zhu AX, Hong TS, Qadan M. Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection. Am J Surg 2019;218:959-66. [PMID: 30871788 DOI: 10.1016/j.amjsurg.2019.02.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
303 Hyder O, Hatzaras I, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Clary BM, Aldrighetti L, Ferrone CR, Zhu AX, Bauer TW, Walters DM, Groeschl R, Gamblin TC, Marsh JW, Nguyen KT, Turley R, Popescu I, Hubert C, Meyer S, Choti MA, Gigot JF, Mentha G, Pawlik TM. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 2013;153:811-8. [PMID: 23499016 DOI: 10.1016/j.surg.2012.12.005] [Cited by in Crossref: 144] [Cited by in F6Publishing: 140] [Article Influence: 16.0] [Reference Citation Analysis]
304 Qin S, Ren Z, Feng YH, Yau T, Wang B, Zhao H, Bai Y, Gu S, Li L, Hernandez S, Xu DZ, Mulla S, Wang Y, Shao H, Cheng AL. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. Liver Cancer 2021;10:296-308. [PMID: 34414118 DOI: 10.1159/000513486] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
305 Sun JH, Zhou GH, Zhang YL, Nie CH, Zhou TY, Ai J, Zhu TY, Wang WL, Zheng SS. Chemoembolization of liver cancer with drug-loading microsphere 50-100μm. Oncotarget 2017;8:5392-9. [PMID: 28036272 DOI: 10.18632/oncotarget.14281] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
306 Salami AC, Barden GM, Castillo DL, Hanna M, Petersen NJ, Davila JA, Naik AD, Anaya DA. Establishment of a Regional Virtual Tumor Board Program to Improve the Process of Care for Patients With Hepatocellular Carcinoma. J Oncol Pract 2015;11:e66-74. [PMID: 25466708 DOI: 10.1200/JOP.2014.000679] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
307 Park JW, Koh YH, Kim HB, Kim HY, An S, Choi JI, Woo SM, Nam BH. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol. 2012;56:1336-1342. [PMID: 22314421 DOI: 10.1016/j.jhep.2012.01.006] [Cited by in Crossref: 101] [Cited by in F6Publishing: 111] [Article Influence: 10.1] [Reference Citation Analysis]
308 Tian X, Dai Y, Wang DQ, Zhang L, Sui CG, Meng FD, Jiang SY, Liu YP, Jiang YH. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis. Drug Des Devel Ther 2015;9:4431-40. [PMID: 26309396 DOI: 10.2147/DDDT.S86629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
309 Rakić M, Patrlj L, Kopljar M, Kliček R, Kolovrat M, Loncar B, Busic Z. Gallbladder cancer. Hepatobiliary Surg Nutr 2014;3:221-6. [PMID: 25392833 DOI: 10.3978/j.issn.2304-3881.2014.09.03] [Cited by in F6Publishing: 64] [Reference Citation Analysis]
310 Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov 2015;5:1040-8. [PMID: 26109333 DOI: 10.1158/2159-8290.CD-15-0274] [Cited by in Crossref: 144] [Cited by in F6Publishing: 87] [Article Influence: 20.6] [Reference Citation Analysis]
311 Wang Y, Luo Q, Li Y, Wang H, Deng S, Wei S, Li X. Quality assessment of clinical practice guidelines on the treatment of hepatocellular carcinoma or metastatic liver cancer. PLoS One. 2014;9:e103939. [PMID: 25105961 DOI: 10.1371/journal.pone.0103939] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
312 Sun JY, Yin T, Zhang XY, Lu XJ. Therapeutic advances for patients with intermediate hepatocellular carcinoma. J Cell Physiol 2019;234:12116-21. [PMID: 30648254 DOI: 10.1002/jcp.28019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
313 Beal EW, Kearney JF, Chakedis JM, James Hanje A, Conteh LF, Black SM, Washburn K, Dittmar KM, Pawlik TM, Dillhoff MR, Schmidt CR. Interval Magnetic Resonance Imaging: an Alternative to Guidelines for Indeterminate Nodules Discovered in the Cirrhotic Liver. J Gastrointest Surg 2017;21:1463-70. [PMID: 28550393 DOI: 10.1007/s11605-017-3454-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
314 Liu M, Liu S, Liu B, Liu B, Guo L, Wang X, Wang Q, Yang S, Dong L. Bulbar Paralysis and Facial Paralysis due to Metastatic Hepatocellular Carcinoma: A Case Report and Literature Review. Medicine (Baltimore) 2016;95:e2632. [PMID: 26825921 DOI: 10.1097/MD.0000000000002632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
315 Li D, Madoff DC. Incorporating Quality of Life Metrics in Interventional Oncology Practice. Semin Intervent Radiol 2017;34:313-21. [PMID: 29249854 DOI: 10.1055/s-0037-1608826] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
316 Oldrini G, Huertas A, Renard-Oldrini S, Taste-George H, Vogin G, Laurent V, Salleron J, Henrot P. Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma. PLoS One 2017;12:e0176118. [PMID: 28441447 DOI: 10.1371/journal.pone.0176118] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
317 Kwon W, Kim H, Han Y, Hwang YJ, Kim SG, Kwon HJ, Vinuela E, Járufe N, Roa JC, Han IW, Heo JS, Choi SH, Choi DW, Ahn KS, Kang KJ, Lee W, Jeong CY, Hong SC, Troncoso AT, Losada HM, Han SS, Park SJ, Kim SW, Yanagimoto H, Endo I, Kubota K, Wakai T, Ajiki T, Adsay NV, Jang JY. Role of tumour location and surgical extent on prognosis in T2 gallbladder cancer: an international multicentre study. Br J Surg 2020;107:1334-43. [PMID: 32452559 DOI: 10.1002/bjs.11618] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
318 Xia F, Lau WY, Qian C, Ma K, Li X, Bie P. Continuous occlusion of hepatic artery proper for prevention of blood loss in partial hepatectomy for ruptured hepatocellular carcinoma: a case-matched comparative study. Ann Surg Oncol 2011;18:1638-43. [PMID: 21181280 DOI: 10.1245/s10434-010-1484-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
319 Nag HH, Nekarakanti PK, Sachan A, Nabi P, Tyagi S. Bi-segmentectomy versus wedge hepatic resection in extended cholecystectomy for T2 and T3 gallbladder cancer: A matched case-control study. Ann Hepatobiliary Pancreat Surg 2021;25:485-91. [PMID: 34845120 DOI: 10.14701/ahbps.2021.25.4.485] [Reference Citation Analysis]
320 Sherman M, Bruix J, Porayko M, Tran T; AASLD Practice Guidelines Committee. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology. 2012;56:793-796. [PMID: 22689409 DOI: 10.1002/hep.25869] [Cited by in Crossref: 104] [Cited by in F6Publishing: 98] [Article Influence: 10.4] [Reference Citation Analysis]
321 Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB, Mulcahy MF, Kulik L, Lewandowski R. Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization. Clinical Gastroenterology and Hepatology 2013;11:1358-1365.e1. [DOI: 10.1016/j.cgh.2013.04.028] [Cited by in Crossref: 127] [Cited by in F6Publishing: 117] [Article Influence: 14.1] [Reference Citation Analysis]
322 Chen H, Sun LY, Zheng HQ, Zhang QF, Jin XM. Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma. Pathology 2012;44:318-24. [PMID: 22531347 DOI: 10.1097/PAT.0b013e328353a24c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
323 Goetze TO, Paolucci V. The prognostic impact of positive lymph nodes in stages T1 to T3 incidental gallbladder carcinoma: results of the German Registry. Surg Endosc. 2012;26:1382-1389. [PMID: 22089259 DOI: 10.1007/s00464-011-2044-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
324 Wang J, Mao Y, Liu Y, Chen Z, Chen M, Lao X, Li S. Hepatocellular Carcinoma in Children and Adolescents: Clinical Characteristics and Treatment. J Gastrointest Surg. 2017;21:1128-1135. [PMID: 28397025 DOI: 10.1007/s11605-017-3420-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
325 Fang AP, Chen PY, Wang XY, Liu ZY, Zhang DM, Luo Y, Liao GC, Long JA, Zhong RH, Zhou ZG, Xu YJ, Xu XJ, Ling WH, Chen MS, Zhang YJ, Zhu HL. Serum copper and zinc levels at diagnosis and hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort. Int J Cancer 2019;144:2823-32. [PMID: 30426509 DOI: 10.1002/ijc.31991] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
326 Hyder O, Dodson RM, Weiss M, Cosgrove DP, Herman JM, Geschwind JH, Kamel IR, Pawlik TM. Trends and patterns of utilization in post-treatment surveillance imaging among patients treated for hepatocellular carcinoma. J Gastrointest Surg. 2013;17:1774-1783. [PMID: 23943387 DOI: 10.1007/s11605-013-2302-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
327 Li GZ, Speicher PJ, Lidsky ME, Darrabie MD, Scarborough JE, White RR, Turley RS, Clary BM. Hepatic resection for hepatocellular carcinoma: do contemporary morbidity and mortality rates demand a transition to ablation as first-line treatment? J Am Coll Surg. 2014;218:827-834. [PMID: 24655879 DOI: 10.1016/j.jamcollsurg.2013.12.036] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
328 Lee DS, Seong J. Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis. Liver Cancer 2014;3:18-30. [PMID: 24804174 DOI: 10.1159/000343855] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
329 Yuan BH, Li RH, Yuan WP, Yang T, Tong TJ, Peng NF, Li LQ, Zhong JH. Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated review. Oncotarget. 2017;8:18537-18549. [PMID: 28061472 DOI: 10.18632/oncotarget.14507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
330 Riedel M, Struve N, Müller-Goebel J, Köcher S, Petersen C, Dikomey E, Rothkamm K, Kriegs M. Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines. Oncotarget 2016;7:61988-95. [PMID: 27542273 DOI: 10.18632/oncotarget.11328] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
331 Zhong JH, Peng NF, You XM, Ma L, Xiang X, Wang YY, Gong WF, Wu FX, Xiang BD, Li LQ. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study. Oncotarget 2017;8:18296-302. [PMID: 28407686 DOI: 10.18632/oncotarget.15433] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
332 Reig M, Torres F, Mariño Z, Forns X, Bruix J. Reply to “Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing”. Journal of Hepatology 2016;65:864-5. [DOI: 10.1016/j.jhep.2016.05.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
333 Gao T, Zhi J, Mu C, Gu S, Xiao J, Yang J, Wang Z, Xiang Y. One-step detection for two serological biomarker species to improve the diagnostic accuracy of hepatocellular carcinoma. Talanta 2018;178:89-93. [DOI: 10.1016/j.talanta.2017.09.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
334 Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer. 2015;4:253-262. [PMID: 26734579 DOI: 10.1159/000367743] [Cited by in Crossref: 73] [Cited by in F6Publishing: 81] [Article Influence: 10.4] [Reference Citation Analysis]
335 Wang ST, Shen SL, Peng BG, Hua YP, Chen B, Kuang M, Li SQ, He Q, Liang LJ. Combined vascular resection and analysis of prognostic factors for hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2015;14:626-32. [PMID: 26663011 DOI: 10.1016/s1499-3872(15)60025-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
336 Rabiee A, Taddei T, Aytaman A, Rogal SS, Kaplan DE, Morgan TR. Development and Implementation of Multidisciplinary Liver Tumor Boards in the Veterans Affairs Health Care System: A 10-Year Experience. Cancers (Basel) 2021;13:4849. [PMID: 34638333 DOI: 10.3390/cancers13194849] [Reference Citation Analysis]
337 Sun X, Li L, Lyu N, Mu L, Lai J, Zhao M. Follow-up schedule for initial recurrent hepatocellular carcinoma after ablation based on risk classification. Cancer Imaging 2020;20:42. [PMID: 32611383 DOI: 10.1186/s40644-020-00319-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
338 Yu F, Lu Z, Chen B, Dong P, Zheng J. microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma. Diagn Pathol 2015;10:129. [PMID: 26215970 DOI: 10.1186/s13000-015-0369-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
339 Huang XT, Huang CS, Li JH, Chen W, Gan TT, Wang XY, Liang LJ, Yin XY. Evaluating the adequacy of nodal status in node-negative gallbladder cancer with T1b-T2 stages: use of nodal staging score. HPB (Oxford) 2021;23:795-801. [PMID: 33051141 DOI: 10.1016/j.hpb.2020.09.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
340 Huguet JM, Lobo M, Labrador JM, Boix C, Albert C, Ferrer-Barceló L, Durá AB, Suárez P, Iranzo I, Gil-Raga M, Burgos CB, Sempere J. Diagnostic-therapeutic management of bile duct cancer. World J Clin Cases 2019; 7(14): 1732-1752 [PMID: 31417920 DOI: 10.12998/wjcc.v7.i14.1732] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
341 Möckelmann N, Rieckmann T, Busch CJ, Becker B, Gleißner L, Hoffer K, Omniczynski M, Steinmeister L, Laban S, Grénman R, Petersen C, Rothkamm K, Dikomey E, Knecht R, Kriegs M. Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells. Oncotarget 2016;7:23542-51. [PMID: 27015558 DOI: 10.18632/oncotarget.8275] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
342 Tan J, Chen X, Du G, Luo Q, Li X, Liu Y, Liang X, Wu J. Multi-dimensional on-particle detection technology for multi-category disease classification. Chem Commun 2016;52:3490-3. [DOI: 10.1039/c5cc09419d] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
343 Laban S, Steinmeister L, Gleißner L, Grob TJ, Grénman R, Petersen C, Gal A, Knecht R, Dikomey E, Kriegs M. Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation. Radiother Oncol 2013;109:286-92. [PMID: 23953412 DOI: 10.1016/j.radonc.2013.07.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
344 Chen Z, Wang T, Chen C, Hong X, Yu J, Ma Y, Guo Y, Huang C, He X, Ju W, Chen M. Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma. J Oncol 2021;2021:7776389. [PMID: 34712326 DOI: 10.1155/2021/7776389] [Reference Citation Analysis]
345 Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J. Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial. Liver Cancer 2021;10:249-59. [PMID: 34239811 DOI: 10.1159/000514420] [Reference Citation Analysis]
346 Farkas SA, Schlitt HJ. [Operative therapy of hepatocellular carcinoma]. Radiologe. 2014;54:673-678. [PMID: 25047523 DOI: 10.1007/s00117-014-2653-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
347 Lee AY, Wu T, Vannier MW, Testa G, Liauw SL. Unresectable Hepatocellular Carcinoma Due to Portal Venous Thrombosis: Focal Stereotactic Body Radiation Therapy Can Promote Resectability. J Gastrointest Cancer 2012;43 Suppl 1:S202-7. [PMID: 22492210 DOI: 10.1007/s12029-012-9387-0] [Reference Citation Analysis]
348 Chen PY, Fang AP, Wang XY, Lan QY, Liao GC, Liu ZY, Zhang DM, Zhang YY, Chen YM, Zhu HL. Adherence to the Chinese or American Dietary Guidelines is Associated with a Lower Risk of Primary Liver Cancer in China: A Case-Control Study. Nutrients 2018;10:E1113. [PMID: 30126134 DOI: 10.3390/nu10081113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]